Markers of autoimmunity in Latent Autoimmune Diabetes in Adults (LADA) and non-diabetic adults: Impact in phenotype and genetic predisposition: Results from the Nord-Trøndelag health study by Sørgjerd, Elin Pettersen
Markers of autoimmunity in 
Latent Autoimmune Diabetes in 
Adults (LADA) and non-diabetic 
adults: Impact in phenotype and 
genetic predisposition
Results from the Nord-Trøndelag health study
Thesis for the degree of Philosophiae Doctor
Levanger, April 2013
Norwegian University of Science and Technology
Faculty of Medicine
Department of Cancer Research and Molecular Medicine
Elin Pettersen Sørgjerd
NTNU
Norwegian University of Science and Technology
Thesis for the degree of Philosophiae Doctor
Faculty of Medicine
Department of Cancer Research and Molecular Medicine
© Elin Pettersen Sørgjerd
ISBN 978-82-471-4326-1 (printed ver.)
ISBN 978-82-471-4327-8 (electronic ver.)
ISSN 1503-8181 
Doctoral theses at NTNU, 2013:113
Printed by NTNU-trykk
Markører for autimmunitet hos pasienter med LADA og en ikke-diabetisk voksen 
befolkning:  påvirkning av fenotype og genetisk predisposisjon.
-Resultater fra Helseundersøkelsen i Nord-Trøndelag.
Diabetes er ikke en enhetlig sykdom, men finnes i flere former. Diabetes er 
hovedsakelig klassifiert i to hovedgrupper; type 1 og type 2 diabetes. Type 1 diabetes er 
en autoimmun sykdom der kroppens immunforsvar angriper og ødelegger beta-cellene 
som produserer insulin. Pasienter med type 2 diabetes har fremdeles bevart en del
insulin produksjon, men en viss grad reduksjon sammen med dårlig insulin virkning på 
cellene i kroppen fører til økende blodsukker og diabetes. I 1986 kom den første 
rapporten om en gruppe pasienter som avvek fra den klassiske type 2 diabetes 
diagnosen. De hadde tegn til autoimmunitet i form av påvisbart antistoff (hovedsakelig 
antiGAD) mot de insulinproduserende beta-cellene i samme grad som type 1 
diabetikere, men pasientene hadde likevel fremdeles god beta-celle funksjon. Pasientene 
kunne i starten kost- og tablett-behandles som type 2 diabetikere før de senere ble 
insulin avhengige, men ofte på et tidligere tidspunkt en type 2 diabetikere. Denne 
pasientgruppen ble etter hvert kalt «Latent Autoimmune Diabetes in Adult» (LADA). I
likhet med type 2 diabetes er LADA pasientene voksne og ofte overvektige og
karakterisert ved såkaldt metabolsk syndrom. Likevel har LADA pasientene høy risiko 
for progresjon mot insulin-avhengighet. Dette tyder på at LADA kan være en 
mellomting mellom type 1 og type 2 diabetes.
LADA har en minst like høy prevalens blant befolkingen som type 1 diabetes.
Men sykdomsbildet til LADA er i mye mindre grad forklart enn hos type 1 og type 2 
diabetes. Målet med denne studien var å kartlegge både den genetiske og fenotypiske
bakgrunnen til LADA. Vi ville også se på hvordan tilstedeværelsen av antiGAD
positivitet påvirket en generell voksen og ikke-diabetisk befolkning. Studien ble basert 
på data fra den andre (1995-1997) og tredje (2006-2008) helseundersøkelsen i Nord-
Trøndelag.
Artikkel 1: Målet var å kartlegge de genetiske risikofaktorene som påvirker
utviklingen av LADA. Dette ble gjort ved å se på allerede kjente risiko gener for både 
type 1 og type 2 diabetes og deres kobling til LADA pasientene som hadde deltatt i
HUNT2. I tillegg ble grad av autoimmunitet hos LADA pasientene bestemt ut fra 
antiGAD titer fra serumprøver. Det ble funnet genetiske likheter med både type 1 og 
type 2 diabetes hos LADA pasientene. Type 1 diabetes genene var assosiert med LADA 
pasienter som hadde høy antiGAD titer, mens type 2 diabetes genene var assosiert med 
LADA pasienter som hadde lav antiGAD titer. Samlet indikerer dataene at LADA 
pasienter med høy autoimmunitet er genetisk mer type 1 diabetes lik, mens LADA 
pasienter med lav autoimmunitet er genetisk mer type 2 diabetes lik. 
Artikkel 2: Målet var å studere den autoimmune prossesen hos LADA 
pasientene både før og etter de hadde fått sin diagnose. Dette ble gjort ved å måle ulike 
antistoffer som man visste var relatert til autoimmunitet hos type 1 diabetes pasienter 
(antiGAD, antiIA-2 og antiZnT8) i LADA pasienter som hadde deltatt i både HUNT2 
og HUNT3. Blant disse LADA pasientene hadde over 50 % ikke lenger de målte 
antistoffene i blodet (antistoff negativ) etter 10 års perioden. LADA pasientene som ble 
antistoff negative var mer type 2 diabetes like - de var bl.a. tykkere og hadde høyere
alder når de fikk sin sykdom enn de som beholdt sin positivitet. Men, de antistoff 
negative LADA pasienten hadde betydelig lavere C-peptidverdier (et mål på egen
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insulinprosduksjon) enn type 2 diabetikere. Dette tyder på at selv en kort periode med 
antistoff positivitet er av klinisk betydning ved at slike LADA pasienter får dårligere
beta-celle funksjon. Det ble også funnet at mange av dem som utviklet LADA i tiden 
etter HUNT2 hadde påvisbart antistoff (antiGAD) i blodet allerede ved HUNT2 – altså 
før de fikk sykdommen. En del LADA pasienter har derfor en lang periode med 
”prediabetes” i form av en pågående autoimmun prosess. LADA pasienter med tidlig 
positivitet for antistoff var mer type 1 diabetes lik sammenlignet med de som var 
antistoff negative ved HUNT2. Disse funnene viser at antistoff mønsteret hos LADA 
pasientene er assosiert med både sykdomsutvikling og fenotype.
Artikkel 3: Tilstedeværelsen og kliniske implikasjoner av antiGAD positivitet i ikke-
diabetiske populasjoner er dårlig belyst. Disse aspektene ble undersøkt prospektivt i et 
utplukk av voksne ikke-diabetikere (n=4496) som hadde deltatt i både HUNT2 og 
HUNT3. AntiGAD positivitet ble funnet i 1,7 % av denne gruppen. Positivitet var ikke 
assosiert med kjønn, første grad familiehistorie med diabetes (FHD), røyking, glukose 
eller BMI. Men HLA-DQA1/DQB1, en risiko-haplotype for autoimmun diabetes ble 
forbundet med antiGAD positivitet. Det samme ble positivitet for antiTPO, et antistoff 
funnet ved hypotyreose med autoimmun årsak. Ca. 50 % av pasientene som var 
antiGAD positive ved HUNT2 var senere antiGAD negative (HUNT3). AntiGAD
positivitet i vedvarende ikke-diabetiske individer er delvis konsistent, er ikke forbundet 
med kliniske parametre relatert til diabetes, men forbundet med HLA risiko og
autoimmunitet i skjoldbruskkjertelen.
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Summary
Diabetes is mainly classified: type 1 and type 2 diabetes. Type 1 diabetes is an 
autoimmune disease in which the body's immune system attacks and destroys the beta 
cells that produce insulin. Patients with type 2 diabetes have somewhat reduced insulin 
production which coupled to poor insulin efficiency leads to increased levels of blood 
glucose. 
In 1986 a group of patients who deviated from the classical type 2 diabetes diagnosis 
was reported. These patients showed signs of autoimmunity in form of detectable 
antibodies (mainly antiGAD) against the insulin-producing beta cells, antibodies which 
are commonly found in type 1 diabetes. The patients had still considerable good beta-
cell function and were initially diet and/or orally treated like type 2 diabetes. However, 
as a group they developed insulin dependency faster than type 2 diabetes. This patient 
group was later called Latent Autoimmune Diabetes in Adult (LADA). As with type 2 
diabetes the LADA patients are older at diagnosis and often overweight. Nevertheless,
the LADA patients display a high risk for progression to insulin dependency. This 
suggests that the etiology of LADA is a mix of type 1 and type 2 diabetes.
The prevalence of LADA is similar to that of type 1 diabetes; however the etiology and 
phenotype of LADA is less characterized than type 1 and type 2 diabetes. The aim of 
this study was therefore primarily to investigate the genetic and phenotypic background 
of LADA. We also looked at the presence and clinical implications of antiGAD 
positivity in a general adult non-diabetic population. The study was based on data from 
the second (HUNT2: 1995-1997) and third (HUNT3:2006-2008) Nord-Trøndelag health 
surveys.
Paper I: The aim was to identify genetic risk factors that could affect the development 
of LADA. This was done by looking at known risk genes for both type 1 and type 2 
diabetes and their link to LADA. Genetic similarities were found with both type 1 and 
type 2 diabetes. Further, the type 1 diabetes genes were associated with LADA with 
higher degree of autoimmunity (high titres of antiGAD), while type 2 diabetes genes 
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were associated with LADA with lower autoimmunity. Overall, the data suggest that 
LADA patients with high autoimmunity are genetically more similar to type 1 diabetes, 
and LADA patients with low autoimmunity are genetically more similar to type 2 
diabetes.
Paper II: The aim was to study the autoimmune process in LADA patients, both before 
and after diagnosis of diabetes. We followed the LADA patients who had participated in 
both HUNT2 and HUNT3 by measuring antibodies that are known to be related to 
autoimmunity in patients with type 1 diabetes (anti-GAD, anti-IA-2 and anti-ZnT8). 
Over 50% of the LADA patients, who had participated in both HUNT2 and HUNT3, 
were antibody negative after the 10-year period between HUNT2 and HUNT3. LADA 
patients who were antibody negative were more type 2 diabetes like; i.e. they were more 
obese and older when they developed diabetes, than those who kept their positivity. 
However, the antibody negative LADA patients had significantly lower C-peptide
values than patients with type 2 diabetes. This suggests that even a short period of 
antibody positivity is of clinical importance. Samples analysed for antiGAD also 
showed that many of the LADA patients who developed LADA after HUNT2 had 
detectable antibody in the blood at HUNT2, i.e. before the onset of the disease. Thus,
for some LADA patients there is a long period of pre-diabetes in the form of an on-
going autoimmune process. LADA patients with positivity for antibodies at HUNT2
were more type 1 diabetes like compared with those who were antibody negative. These 
findings show that the antibody patterns in LADA patients affect the LADA patients' 
disease progression and phenotype.
Paper III: The presence and clinical implications of antiGAD positivity in non-diabetic 
populations are poorly elucidated. We examined these aspects prospectively in a cohort
of adult non-diabetic patients (n = 4496) who had participated in both HUNT2 and 
HUNT3. AntiGAD positivity was found in 1.7% of the group. Positivity was not 
associated with gender, first-degree family history of diabetes (FHD), smoking, glucose 
or BMI. However, the HLA-DQA1/DQB1 haplotype, a known risk haplotype for type 1
diabetes was associated with antiGAD positivity. Association was also found  with 
positivity for antiTPO, an antibody found in hypothyroidism. Approximately 50% of the 
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patients who were positive by antiGAD at HUNT2 had turned antiGAD negative at 
HUNT3. We conclude that antiGAD positivity in persistently non-diabetic individuals 
is partly consistent, is not associated with clinical parameters related to diabetes, but is 
associated with high risk HLA haplotypes and autoimmunity in the thyroid gland.
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1 Introduction
1.1 World-wide scope of diabetes and classification
Diabetes mellitus is a chronic metabolic disorder characterized by increased plasma 
glucose occurring when insulin is not acting as it should (insulin resistance) and/or the 
insulin production from pancreas is poor (insulin deficiency). According to the 
International Diabetes Federation (IDF), there are today estimated more than 350
million people worldwide with diabetes and the incidence every year is still rising1
(http://www.idf.org/diabetesatlas). Diabetes has become a serious global health
problem. Despite the effort of many researchers across the world, the etiology of the 
disease is still not fully elucidated. However, investigations support the fact that 
diabetes is a heterogeneous disease.
The World Health Organization (WHO) has since 1965 given advice on definitions,
diagnosis and classifications of diabetes based on published epidemiological studies 
regarding etiology and pathogenesis of diabetes. Before 1999 the major forms of 
diabetes were classified by type of treatment: e.g. insulin dependence or non-insulin 
dependence at diagnosis. In the late 1990ies, an international expert committee,
sponsored by the American Diabetes Association (ADA), and WHO recommended a 
change in the classification system from a treatment-based one to one more based on 
etiology2,3. Diabetes primarily caused by beta-cell destruction and prone to ketoacidosis 
should then be classified as type 1 diabetes. Type 1 diabetes includes two subgroups; A)
the major subgroup, autoimmune diabetes, with beta-cell destruction due to an
autoimmune process and B) a minor subgroup, idiopathic diabetes, where beta-cell 
destruction is evident but (as of today) no evidence of autoimmunity has been found.
Diabetic patients who do not have signs of autoimmunity, who are insulin resistant and 
who have to some degree insulin deficiency are classified as type 2 diabetes. Other 
types of diabetes including gestational diabetes, genetic syndromes and monogenic 
disorders including maturity-onset diabetes of the young are not the main focus of this 
study.
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1.2 Type 1 diabetes
In general
Type 1 diabetes manifests itself in all age groups and accounts for about 10% of all 
diabetic cases. The disease is mainly caused by an immune-mediated destruction of the 
insulin producing beta cells in the pancreas. Diabetes becomes overt when the beta cells 
are no longer able to meet the body’s requirement of insulin4. This leads to reliance on 
insulin treatment.
The epidemiology and etiology
The disease is found in all ethnic groups; however, it is more prevalent in European
populations, especially in the Northern countries, with Finland showing the highest 
incidence rate. Most studies show a worldwide rapid increase in incidence of childhood
type 1 diabetes5-7. The epidemiological studies are mainly performed in children and 
therefore little is known about the trends in incidence rates in adults. 
Type 1 diabetes is a multifactorial disease where both gene predispositions and 
environmental factors interact. There is a high familial aggregation of type 1 diabetes, 
with up to 15-fold higher risk of developing the disease in siblings compared to the 
general population8. As outlined below, a predisposing genetic background is indeed a 
strong factor. However, 90% of the type 1 diabetic patients do not have a first degree 
relative with type 1 diabetes. This indicates also a strong influence by environmental 
factors4. Potential environmental factors include diet (e.g. breast vs. bottle feeding and 
D-vitamin intake), environmental toxins (e.g. nitrosamines) and viral infections both 
intrauterine and in childhood (e.g. enteroviruses and congenital rubella), however the 
evidence for the importance of such factors is conflicting9-14. The “hygiene hypothesis”
proposes that improved hygiene and living conditions in the 20th century have decreased
the frequency of childhood infections. This situation may then modulate the immune
system and increase the risk for type 1 diabetes and also other autoimmune diseases15.
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Genetics 
The strongest susceptibility genes for type 1 diabetes are found in the human leukocyte 
antigen (HLA) class II genes which account for almost 50% of the genetic risk16. These 
genes are located in the Major Histocompatibility Complex (MHC), on the short arm of 
chromosome 6. The HLA haplotypes DQA1*03:01-DQB1*03:02 (DQ8) and 
DQA1*05:01-DQB1*02:01 (DQ2) are the two high risk haplotypes known to be 
associated most strongly with type 1 diabetes17-20. About 90% of type 1 diabetic 
children have at least one or both of these high risk haplotypes. On the other hand 
DQA1*01:02-DQB1*06:02 is a strongly protective HLA haplotype with a frequency of
about 20% in the general population and <1% in individuals with type 1 diabetes17. This 
protection is not absolute since some patients with type 1 diabetes are found to harbor
the protective DQB1*06:02 allele21. The mechanism behind why DQ2 and DQ8 are 
important risk factors for type 1 diabetes remains to be fully elucidated. A leading 
hypothesis relates to the three-dimensional configuration of different haplotypes for the 
groove that harbors a presenting antigen (see further below).
Before the advent of genome wide association studies (GWAS) only a few non-HLA 
loci had been found to be associated with type 1 diabetes, such as the insulin gene
(INS)22, protein tyrosine phosphatase, non-receptor type 22 (PTPN22)23,24, cytotoxic T-
lymphocyte-associated protein-4 (CTLA4)25 and interleukin-2 receptor-alpha 
(IL2RA)26,27. In the last five-six years the numbers of susceptibility genes associated 
with type 1 diabetes have increased due to GWAS. More than 40 genetic markers with 
an underlying risk of developing type 1 diabetes have been identified28-32. Many of 
these genes are suggested to influence immune function or beta-cell function and their 
discovery may be important for the identification of different disease pathways33. The 
impact of these genes on the development of type 1 diabetes is however limited 
compared to certain of the HLA haplotypes.
The risk allele of the INS gene (class I allele) associates with decreased insulin levels in 
both the pancreas and in the thymus. Lower expression of insulin in the thymus is 
suggested to affect the specialized antigen presenting cells in the thymus and in the 
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elimination of autoreactive T-cells something that could influence the development of 
autoimmunity33,34. The PTPN22 gene codes for the lymphoid protein tyrosine 
phosphatase (LYP) that, together with Csk kinase, suppresses T-cell activation24. The 
risk allele of PTPN22 (arginine to tryptophan) is found to disrupt the interaction 
between LYP and Csk, resulting in weakened suppression of autoreactive T-cells.
Molecular pathogenesis
The severe reduction or abolishment of insulin production in type 1 diabetes is thought 
to occur due to an irreversible T-cell mediated autoimmune destruction of the insulin-
producing pancreatic beta-cells12. One of the hypotheses to explain this T-cell response 
includes the so-called trimolecular complex35. This complex consists of the T-cell 
receptor (TCR), an antigenic peptide, and a HLA molecule on antigen-presenting cells 
(APCs). The APCs present the peptide, which is bound to the HLA molecules on the 
surface of an APC, to the TCR. The TCR is then able to recognize it and with varying 
affinity bind to the peptide. The TCR is crucial for T-cell selection in the thymus. If the 
TCR recognition of a certain self-peptide is modest (due to weak binding) thymus may 
fail to “kill” autoreactive T-cells which can then react with self-antigens in the 
periphery and trigger an immune response that may end in tissue destruction.
T-cell activation is regarded as the major cause of autoimmunity in type 1 diabetes. 
However, there are also signs of humoral autoimmunity in form of antibodies against
islet proteins36-39. Well-documented antibodies that are of clinical interest are glutamic 
acid decarboxylase (antiGAD), tyrosine phosphatase-like protein insulinoma antigen-2
(antiIA-2), insulin (antiIA), zinc transporter 8 (antiZnT8) and islet cell cytoplasmic 
antibody (ICA). These antibodies are described in more detail below.
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1.2 Type 2 diabetes
In general
Type 2 diabetes is the most common type of diabetes and comprises more than 80% of 
the diabetic population world-wide. Patients with type 2 diabetes are characterized by
being insulin resistant and/or having inadequate insulin secretion with the disease 
typically developing in adulthood and old age. Type 2 diabetes is usually, but not 
always, accompanied by obesity.
The epidemiology and etiology
The incidence of type 2 diabetes has been rising in all age groups even in children,
although the risk of type 2 diabetes increases with age. The increase may be due to more 
people getting obese. Regions with the highest prevalence of diabetes in adults are the 
Middle East and North Africa followed by North America and the Caribbean (data from 
2011)1.
Type 2 diabetes, like type 1 diabetes, is a heterogeneous disorder; however both the
predisposing genes and environmental factors involved are different from the ones 
implicated in type 1 diabetes. Behavioral risk factors like overweight, smoking, diet and 
lack of physical activity are strongly associated with type 2 diabetes, with overweight as 
the most important one40-42. It has been estimated that approximately 80% of all new 
type 2 diabetes cases are due to overweight43 and both physical activity and a healthy 
diet significantly reduce the risk of type 2 diabetes41,44. Also low birth weight, which is 
an indicator of fetal malnutrition, is a risk factor for developing type 2 diabetes later in 
life45-47.
Genetics 
The heritability of type 2 diabetes is as high as in type 1 diabetes40. However, the risk 
genes so far documented for type 2 diabetes only explain a small part of the risk 
deduced from family history. This is in contrast to the situation in type 1 diabetes. A 
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“simplified” conclusion would be that environmental factors are well documented in 
type 2 diabetes, genetic factors less so, whereas the opposite is true for type 1 diabetes.
The genes coding for calpain 10 (CAPN10), transcription factor-7-like 2 (TCF7L2), the 
pancreatic beta cell KATP channel subunit Kir6.2 (KCNJ11), peroxisome proliferator-
activated receptor gamma (PPARG) and wolframin (WFS1) were the first genes to be 
associated with type 2 diabetes through linkage and candidate gene studies48-52. Many 
more risk loci have later been identified through GWAS and meta-analysis53-55. The 
majority of the genes found are considered to be important for reduced insulin secretion 
through reduced beta-cell mass and beta cell dysfunction. This pertains to the TCF7L2,
HHEX, KCNJ11, WFS1, HNF1B, SLC30A8, CDKAL1, IGF2BP2, CDKN2A, CDKN2B,
THADA, TSPAN8 and KCNQ1 genes56-58. Only a few genes, such as 33$5Ȗ ,56
ADAMTS9 and FTO, affect insulin sensitivity57,58. The FTO gene is also strongly 
associated with obesity59,60. The clinical pay-off of genetic studies in type 2 diabetes has 
however been minor. Hence, the associations found have modest effect sizes and the 
associated genes have limited predictive ability, and only 5-10% of the genetic 
susceptibility is currently explained57,61.
Pathogenesis and treatment
Hyperglycemia, which leads to development of type 2 diabetes, occurs because of a
combinations of A) insulin resistance in different tissues in the body most importantly
skeletal muscles, adipose tissue and liver and B) beta-cell defects and/or reduced beta-
cell mass leading to impaired insulin secretion. During pre-diabetes the beta-cell is still 
able to compensate for the insulin resistance and produces enough insulin to maintain 
normal glucose levels. At onset of type 2 diabetes one finds disparity between insulin 
and glucose levels. Thus insulin levels are “normal” despite high glucose levels which 
should have resulted in elevated insulin levels. This indicates that the insulin secretion 
is no longer able to compensate for the insulin resistance62. It is still unclear whether a
reduction in beta-cell mass or cellular signal secretion defects is the most important 
factor behind insufficient insulin secretion.
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Obesity, especially with abdominal fat distribution, (a feature which is more strongly 
associated with type 2 diabetes than body mass index, BMI), lowers insulin 
sensitivity63. The degree to which the beta cells are able to compensate for the insulin 
resistance determines whether type 2 diabetes develops or not.
At diagnosis patients with type 2 diabetes are still able to produce much insulin and the 
disease can usually be treated with diet and oral antidiabetic drugs. As the disease 
progresses many patients gradually lose their ability to produce insulin and will 
therefore eventually benefit from insulin treatment.
1.3 Latent autoimmune diabetes in adult 
In general
Adult patients with signs of autoimmunity may masquerade as type 2 diabetes64,65.
These patients are termed slow-onset type 1 diabetes or more commonly latent 
autoimmune diabetes in adult (LADA). There is still an ongoing discussion whether 
LADA is a subgroup of type 1 diabetes, a mixture of type 1 and type 2 diabetes or an 
entity of its own. However, by WHO definitions, LADA is classified as type 1 diabetes
or autoimmune diabetes3.
The epidemiology and etiology
The frequency of LADA among diabetic patients varies between 4-10% in different 
populations indicating that the prevalence of LADA is as high as type 1 diabetes66,67.
There are few reports on the incidence of LADA. Available information indicates about 
10 per 100,000 people per year68,69.
Clinical features of LADA share similarities with both type 1 and type 2 diabetes. 
LADA patients, like type 1 diabetes, have (by definition) autoantibodies indicating an 
autoimmune disease, but are more likely to be positive for only one antibody than being 
multiple antibody positive70. Similar to type 2 diabetic patients, LADA patients develop 
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diabetes as adults, and are often, but not always, overweight. Compared to type 1 
diabetic patient LADA patients have higher C-peptide levels and do not need insulin 
treatment at diagnosis66,71,72. LADA patients are, however, more prone to progress 
earlier to insulin dependence than patients with type 2 diabetes.
Age, antibody positivity and initiation time of insulin treatment are common criteria 
used to classify LADA. However, definition of these criteria varies between studies.
Some studies use no age limit73,74, others use cut-offs like age >3068,72 years or >35
years75. LADA patients should be antibody positive for at least one antibody, however
which antibody is not defined. AntiGAD is the most commonly used and also shown to 
be the most prevalent one in LADA70. LADA patients should be non-insulin dependent 
at diagnosis, but for how long after diagnosis is unclear. Some studies use three
months74, others six months68 and some use up to 12 months73.
Genetics of LADA
The genetic risk factors of LADA have not been elucidated to the same extent as for
type 1 and type 2 diabetes. Some evidence suggest that the genetic risk of LADA is a
mixture of type 1 and type 2 diabetes associated genes as described below. 
Like in type 1 diabetes, the high risk HLA-DQB1*03:02 and DQB1*02:01 alleles are
associated with a higher risk of developing LADA66,74,76. However, compared to type 1 
diabetes, the frequency of the high risk HLA alleles DQB1*03:02/*02:01 is reported to 
be lower and the highly protective allele DQB1*06:02 is higher in LADA66. Studies
have also reported that increased frequency of HLA-DQB1*02:01 may be the most 
prevalent risk HLA allele in LADA67,74. Regarding susceptibility genes in addition to 
HLA the INS gene, as well as the PTPN22 and the CTLA4 genes, are reported to be 
associated with higher risk in LADA76-78.
When this study started in the fall 2007, there had been few studies looking at the 
association between susceptibility genes for type 2 diabetes and LADA. A few studies 
reported that the TCF7L2 gene, highly associated with type 2 diabetes, was also
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associated with LADA76,79-81. There were no reports on genes associated with LADA
only.
Pathophysiology of LADA
Available results on LADA indicate an interaction of both autoimmunity (shown by
presence of antibodies) and insulin resistance. On one hand studies have shown that 
LADA patients require insulin after a much shorter time subsequent to diagnosis 
compared to type 2 diabetic patients73,82. Hence, an autoimmune attack against the beta-
cells in LADA patients is bound to have an impact over time, although at a slower rate
than in type 1 diabetic patients.  In line with an impact of autoimmunity on insulin 
producing cells, the levels of antibodies like antiGAD correlate with a need of insulin 
treatment among LADA patients73. On the other hand, many patients with LADA are 
obese, with obesity being a marker of insulin resistance, and studies have shown insulin 
resistance in LADA patients to the same degree as in type 2 diabetic patients71,83.
1.5 Antibodies in autoimmune diabetes
In general
The first autoantibody found to be associated with type 1 diabetes was the ICA84,85.
Later several other autoantibodies have been defined. These includes antibodies against 
GAD36, insulin39, IA-238 and most recently ZnT837.
ICA is detected by indirect immunofluorescence on cryocut sections of human pancreas.
This antibody is difficult to measure since the method is labor-intensive and requires 
human pancreas. AntiGAD, antiIA-2, antiIA and antiZnT8 are usually analyzed by 
immunoprecipitation (radiobinding) assays (RIA) with 3H- or 35S-methionine as labeled 
reagent. However, also enzyme-linked immunosorbent assays (ELISA) are used. 
Several international workshops, in particular the Diabetes Autoantibody 
Standardization Program (DASP) which was established in 2000, have resulted in 
standardization of the antibody assays. This has over the years led to improvement of 
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both the sensitivity and specificity of the assays86-88. Presently, measurements of 
autoantibody markers are the most reliable diagnostic tool to identify and predict type 1 
diabetes88.
There is still no evidence that these antibodies have an active role in development of 
type 1 diabetes. Rather, they appear to reflect an ongoing autoimmune process. Thus
development of autoimmune diabetes is strongly associated with the presence of 
autoantibody markers. About 90-95% of newly diagnosed type 1 diabetic patients are 
positive for at least one antibody89,90. It is also well known that antibodies can be 
present months and up to several years before clinical diagnosis of type 1 diabetes, 
indicating a long pre-diabetic phase with autoimmune activity91-93. Further, the 
appearance of multiple antibodies is highly predictable of the development of type 1 
diabetes94,95.
AntiGAD
Glutamic acid decarboxylase (GAD) is an enzyme which catalyzes the conversion of 
glutamic acid to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). 
GAD was by Baekkeskov et al in 199036 discovered to be the 64kDa beta-cell antigen
which earlier was found to be a target of antibodies in type 1 diabetes. GAD is found to 
be highly expressed in the nervous system, but is also found in other tissues such as
pancreas96. The function of GAD in the pancreas is not clear, however the presence of 
both GAD and GABA and of GABA receptors on the islet beta cells suggests that
GABA is involved in paracrine signaling within these cells97. Other isoforms of GAD 
like the 67kDa GAD (GAD67) have been discovered98, but have added little to the 
detection of type 1 diabetes compared to antibodies against the 64kDa GAD99.
AntiGAD is present in up to 80% of new-onset type 1 diabetic patients100. AntiGAD
does not seem to be influenced by age to the same extent as antiIA and ICA101,102.
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AntiIA-2
The tyrosine phosphatase-like protein insulinoma antigen-2 (IA-2) is an enzymatically 
inactive member of the tyrosine phosphatase family. It is a transmembrane glycoprotein 
located in islet secretory granules and may be involved in insulin secretion103. AntiIA-2
was identified when the 64kDa immunoprecipitate was trypsin treated and revealed 
three different fragments of 37kDa, 40kDa and 50kDa. The 50kDa fragment was 
identified by GAD antibodies; however the 37kDa and 40kDa fragments seemed to be 
derived from a different autoantigen which was found to be IA-238.
AntiIA-2 is found in about 80% of newly diagnosed type 1 diabetic patients. This 
antibody is found to have higher prevalence in younger age groups compared to 
adults104.
AntiZnT8
In 2004 Chimienti et al. identified and cloned a beta-cell specific zinc transporter 8
(ZnT8) which is a product of the gene SLC30A105. The zinc transporter was found to be 
localized together with insulin in the insulin secretory granules. Since zinc is an 
important part of insulin storage and secretion, ZnT8 is believed to play an important 
role for maintaining zinc in the beta-cells, something which is necessary for insulin 
maturation and storage106. Antibodies against ZnT8 are the fourth major and the most 
recently identified antibody marker in autoimmune diabetes37. AntiZnT8 has been 
found in about 60-80% of newly diagnosed type 1 diabetic cases90,107,108 and 10-20% of
LADA patients70,109,110. Some studies have also shown that AntiZnT8 is present in about 
1-7% of patients originally diagnosed with type 2 diabetes and presumably antibody 
negative70,111.
1.6 AntiGAD in the general non-diabetic population
Previous studies in adults and school children have shown that antibodies, in particular 
antiGAD, are present in a minority of non-diabetic subjects who do not have close 
relatives with autoimmune diabetes94,112-115. The frequency (which varies between 1-4%
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between studies) and the clinical importance of antiGAD in non-diabetic individuals is 
however still unclear and debated. It is still not known if the presence of anti-GAD in 
adult non-diabetic individuals reflects an extremely slow progress of beta-cell 
destruction or whether it is attributable to other factors, such as aging. It has been 
argued that positivity under these conditions does not predict the development of 
diabetes116,117, that it is unspecific (particularly if it is weak), and should be regarded as 
falsely positive118. However, it is also reported that the high risk type 1 diabetes HLA
haplotypes are associated with antiGAD positivity and high antiGAD levels in adult 
non-diabetic individuals from the general population112,119. This may indicate that a
genetic predisposition can induce antibody positivity, but that other factors drive or are 
at least necessary for development of autoimmune mediated diabetes.
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2 Aims
The specific aims of this study were to investigate;
1) A: the association of type 1 and type 2 diabetes candidate genes in LADA 
patients compared to non-diabetic controls and B: the variability of the genetic 
background in LADA patients in relation to a marker of autoimmunity 
(antiGAD titre) and to a phenotypic risk factor for type 2 diabetes (BMI) (Paper 
I).
2) A: prospectively the pre-diabetic appearance of antiGAD, antiIA-2 and 
antiZnT8, B: the persistence of these antibodies in LADA patients after a 10-13
years follow-up and C: cross-sectionally the presence of the same antibodies in 
LADA and adult-onset type 1 diabetes in relation to diabetes onset and other 
phenotypic characteristics (Paper II)
3) The prevalence, persistence and the potential clinical impact of antiGAD 
positivity in a persistently non-diabetic population of adults (Paper III).
.
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3 Methods
3.1 Study population
The HUNT Study 
The Nord-Trøndelag health Study (HUNT) consist of three health surveys performed in 
1984-1986 (HUNT1), 1995-1997 (HUNT2) and 2006-2008 (HUNT3). In all three 
surveys WKH HQWLUH DGXOW SRSXODWLRQ DJHG  years) in the Nord-Trøndelag county
located in the central part of Norway (Figure 3.1), were invited to participate (n=87,259
in HUNT1, n=93,898 in HUNT2 and n=93,860 in HUNT3). The participants who
formed the basis of our study were collected from the HUNT2 and HUNT3 surveys. 
Figure 3.1: Norway and the location of Nord-Trøndelag County 
The HUNT2 survey had an overall response rate of 69.5% (n=65,237). The survey 
included a clinical examination (including blood pressure and anthropometric 
measurements), non-fasting blood sampling and two basic questionnaires (Q1:
Appendix I and Q2) which included more than 200 health-related items. The HUNT2 
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survey has been described in detail elsewhere120. The HUNT3 survey had an overall 
response rate of 54.1% (n=50,807). Fifty-seven percent of the participants in HUNT2 
also participated in HUNT3 (n=37,059). The HUNT3 survey had a similar design as 
HUNT2 and thus included clinical examination, blood-sampling and two basic 
questionnaires (Q1: Appendix II and Q2) as described in detail121. Biological samples 
collected from HUNT2 and HUNT3 were stored at HUNT Biobank (Levanger, 
Norway) prior to analysis, serum being stored at minus 70oC and DNA at minus 20oC.
Data collection
Papers I, II and III
Individuals with diabetes were identified from a self-reported answer of “Yes” to the 
question “Do you have or have you had diabetes?” in the Q1 questionnaire from 
HUNT2 and HUNT3. In HUNT2, 1,972 individuals and in HUNT3 2,189 answered 
affirmative. At both HUNT2 and HUNT3 participants declaring diabetes were invited to 
a diabetes-oriented follow-up investigation. They completed a more detailed 
questionnaire concerning diabetes (HUNT2: Appendix III and HUNT3: Appendix IV)
and underwent an interview by a nurse to ensure year of diagnosis and details on type 
and start of treatment. They furthermore provided a fasting blood sample for 
measurements of blood glucose, serum C-peptide, and antiGAD. In HUNT3 antiIA-2
was also measured. A total of 1,630 and 1,824 participants filled out the diabetes-
oriented questionnaire and a total of 1,455 and 1,168 participants rendered a fasting 
blood sample at the follow-up respectively in HUNT2 and HUNT3.
Subsequent to the surveys we additionally analyzed antiGAD in participants who had 
declared diabetes but had not provided a blood sample at the follow-up, but had serum 
available from the baseline blood sampling (n=432 in HUNT2 and n=984 in HUNT3).
Analysis of antiGAD in the HUNT2 samples was performed in the spring of 2008
(average 12 years after sampling) and the HUNT3 samples were analyzed in late 2009
(average 3 years after sampling). This gave us the opportunity to classify all cases who 
had answered affirmative to the question on diabetes.
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Participants who answered “no” to the question of having diabetes served as controls.
They were frequency-matched by sex and by 10 year of age category to the diabetic 
patients. 
Paper III
Equal numbers of men and women who had stated that they did not have diabetes both 
at the HUNT2 and HUNT3 surveys were randomly selected from different age groups:
500 individuals from the age group 20-29 years, 500 from the age group 30-34 years
etc. up to the last age group of 65 years and above. Altogether a total of 4,500 non-
diabetic individuals were sampled to represent the general adult population. 
Classification of diabetes
Diabetic cases were classified as having type 1 diabetes if they had started insulin 
treatment within 12 months of diagnosis and were 1) antibody positive, or 2) antibody
negative but in addition had fasting C-peptide levels <150 pmol/l.
Cases were classified as having LADA if they were antibody positive and had not been 
treated with insulin within 12 months of diagnosis. No age limit was set for LADA. 
Cases were classified as having type 2 diabetes if they were antibody negative and had
not been treated with insulin within 12 months of diagnosis.
Classification of diabetic cases with missing data on insulin treatment (paper I)
For the identified diabetic cases in HUNT2 who did not attend the follow-up
investigation we lacked data on insulin treatment. These non-attendees were therefore 
classified by less stringent criteria; i.e. as type 1 diabetes if antiGAD positive and age at 
diagnosis 35 years old, LADA if antiGAD positive and age at diagnosis >35 years old 
and as type 2 diabetes if antiGAD negative and age of diagnosis >35 years old. 
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Attended follow-up 
n=1,455
Diabetes
n=1,972
Did not attend the 
follow-up
n=517
LADA
n=126
Type 2 diabetes
n=1090
Type 1 diabetes
n=120
Non-diabetic
Controls
n=1503
HUNT2 Population
n=65,237
Analysed for 
antiGAD n=432
LADA
n=18
Type 2 diabetes
n=255
Type 1 diabetes
n=16
262 excluded due to
missing DNA, other 
types of  diabetes or 
non-classifiable
85 excluded due to
missing serum
Figure 3.2: Study population in paper I.
Final study population
Paper I
This was a case-control study nested within the HUNT2 cohort (Figure 3.2). All 
diabetic cases identified at baseline who had DNA available (n=1,642) and 1,503 age 
and gender matched healthy non-diabetic controls were included in the study. The 
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diabetic cases classified by the criteria that included insulin treatment, comprised of 120
type 1 diabetic patients, 126 LADA patients and 1,090 type 2 diabetic patients. Sixteen
type 1 diabetic, 18 LADA and 255 type 2 diabetic patients were classified by the less 
stringent criteria. Cases that we were not able to classify (n=17) were excluded.
Paper II
This was both a prospective and a cross-sectional study. Serum samples were collected 
from the diabetic subjects classified as type 1 diabetes and LADA from both the 
HUNT2 and HUNT3 surveys. Diabetic cases were analyzed for antiIA-2 (if not done 
already in HUNT3) and for antiZnT8. Also serum samples from HUNT2 were used to 
analyze antiGAD, antiIA-2 and antiZnT8 in incident cases in HUNT3 (i.e. in those not 
having a diagnosis of diabetes in HUNT2). All of these antibody measurements were 
done in late 2009.
For LADA and type 1 diabetic cases we included for analysis those with complete data 
on all three antibody assays. These cases comprised 120 type 1 diabetic and 120 LADA 
cases from HUNT2 and 147 type 1 diabetic and 85 LADA cases from HUNT3 (Figure 
3.3). Type 2 diabetic cases who had participated in both HUNT2 and HUNT3 surveys
(n=302) were also included for comparison.
Prospective data were obtained (i.e. from cases that had participated in both HUNT2 
and HUNT3; providing 10-13 years of follow-up) on 44 LADA, 59 type 1 diabetic and 
302 type 2 diabetic cases from HUNT2 who were followed to HUNT. In addition we 
analyzed data from 31 LADA and 24 type 1 incident cases of diabetes from HUNT3
who also participated and were non-diabetic in HUNT2.
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Not attended HUNT3
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T1D
N=147
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N=85
Participated both surveys
T1D
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LADA
N=44
Incidents HUNT3 Incidents HUNT3
Figure 3.3: Study population in paper II. T1D = type 1 diabetes
Paper III
This was a prospective study. Serum samples from HUNT2 to be used for antiGAD 
measurements were available from 4,496 of the 4,500 selected individuals (Figure 3.4).
All individuals who were antiGAD positive in HUNT2 were analysed for positivity in 
HUNT3. For these individuals antiGAD was measured in the fall of 2011.
Additionally, 55 incident diabetic cases (Figure 3.4) who developed autoimmune 
diabetes between HUNT2 and HUNT3 (i.e. reported not having diabetes in HUNT2 but 
reported having diabetes in HUNT3, n=24 type 1 diabetes and n=31 LADA) were
included for analysis. Thirty-three of these cases were antiGAD positive already at
HUNT2, i.e. several years before diagnosis (n=13 type 1 diabetes and n=21 LADA).
Data from these patients who over time developed diabetes, were compared with data 
from the antiGAD positive persistently non-diabetic population.
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Persistently non-diabetic individuals who were antiGAD positive at HUNT2 as well as
a control group of antiGAD negative non-diabetic individuals were typed for HLA-
DQA1 and HLA- DQB1. A control group was age and gender matched to the antiGAD 
positive, non-diabetic group. Two controls were selected per antiGAD positive 
individual. The same HLA genotypes were also analysed in individuals who developed 
autoimmune diabetes during the interval between HUNT2 and HUNT3.
N=4530 
Participants HUNT2
Non-diabetic 
HUNT2
N=4496
Pre-diabetic 
antiGAD pos 
HUNT2
N=34
N=76
AntiGAD pos 
HUNT2
N=4420
AntiGAD neg 
HUNT2
N=35
Anti-GAD pos
HUNT3
N=34
Autoimmune 
diabetes in 
HUNT3
Persistently non-diabetic 
HUNT3
N=41
Anti-GAD neg
HUNT3
Figure 3.4: Study population paper III
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3.2 Biochemical analysis
C-peptide measurements
The most common way to assess insulin secretion is by measurements of C-peptide. C-
peptide is a cleavage product from pro-insulin and is released together with insulin. C-
peptide is therefore a measure of insulin release.
Serum levels of C-peptide were analysed at the Hormone Laboratory of Aker Hormone 
laboratory, Oslo University hospital (Oslo, Norway) by radioimmunoassay (Diagnostic 
system Laboratories, USA).
Antibody measurements
All antibody measurements were carried out at the Aker Hormone laboratory, Oslo 
University hospital (Oslo, Norway).
AntiGAD
AntiGAD was measured by immuno-precipitation using translation labeled 3H-GAD65 
as labeled reagent (Novo Nordisk, Denmark). Separation of bound antiGAD and free 
labeled antigen was done by protein A coupled to Sepharose (procedure developed at 
the Hormone laboratory). Antibody levels were expressed as an antibody index (ai) 
relative to a standard serum given by the formula [(counts per minute (cpm) in the 
patients sample – cpm from negative reference sample) / (cpm of a positive reference 
sample – cpm from negative reference sample)]. The lower limit of detection was 
0.01ai, whereas no upper limit was defined. Intra-assay variation coefficient (CV) was 
14% in the lowest (0.11ai), 8% in the middle (0.22ai) and 17% in the highest (2.0ai) 
range of measurements. Total assay CV was 19% in the lower (0.21ai) and 23% in the 
higher (0.66ai) measurement range.
In paper I and II an antibody index of 0.08ai or greater was considered positive. This 
cut-off level of positivity was the one used by the Hormone laboratory based on 
participation in DASP.  Cut-off was set to achieve the highest possible specificity with 
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an acceptable corresponding sensitivity. Based on participation in DASP this 
corresponds to a 68% workshop-sensitivity and 100% workshop-specificity.
In paper III subjects above the 98.5th percentile of the antiGAD levels in the total 
cohort were considered to be antiGAD “positive”. This corresponded to a value >0.05ai. 
Based on Aker Hormone Laboratory’s participation in DASP this corresponded to an 
82% workshop-sensitivity and a 99% workshop-specificity.
AntiIA-2
Antibody to IA-2 was measured by immuno-precipitation using translation labeled 3H-
IA-2ic as a labeled reagent. Separation of bound antiIA-2 and free labeled antigen was 
done by protein A coupled to Sepharose, using a procedure developed at the Hormone 
laboratory. Antibody levels were expressed as an index value relative to a standard 
serum. A value of 0.11ai or greater was considered positive (method range: 0.01-
3.00ai). The level of cut-off was based on the same considerations as for antiGAD. As 
calculated from DASP 2003 this assay has 70% workshop-sensitivity and 99% 
workshop-specificity. Intra-assay CV was 17% in the lowest (0.10 ai), 10% in the 
middle (0.48 ai) and 7% in the highest (1.96 ai) range of measurements. Total assay CV 
was 22% in the lower (0.14 ai) and 11% in the higher (3.60 ai) range of measurements. 
AntiZnT8
AntiZnT8 was measured by immuno-precipitation using a translation labeled 3H-ZnT8 
C-terminal Arg325 variant fused to C-terminal Trp325 variant as a labeled reagent
(based on a plasmid pJH5.2 SP6, a Dimer human ZnT8 C-terminal Arg325 variant 
fused to human ZnT8 C-terminal Trp variant from Dr. Hutton, University of Colorado, 
Denver, CO, USA). Separation of bound antiZnT8 and freely labeled antigen was 
achieved by protein A plus protein C coupled to Sepharose using a procedure developed 
at the Hormone laboratory. Antibody levels were expressed as an index value relative to 
a standard serum. A value greater of 0.08ai was considered positive (method range: 
>0.01 ai). The level of cut-off was based on the same considerations as for antiGAD. As 
calculated from DASP 2010 the antiZnT8 assay has 46% workshop-sensitivity and
100% workshop-specificity. Intra-assay CV was 7% in the lowest (0.18 ai) and 6% in 
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the highest (0.88 ai) range measurements. Total assay CV was 20% in the lower (0.18 
ai) and 16% in the higher (0.85 ai) range of measurements.
3.3 Genetic analysis
DNA extraction
DNA samples were mainly collected from the HUNT2 survey. DNA from HUNT2 was 
extracted from peripheral blood leukocytes from EDTA whole blood or blood clots 
using the Gentra Purgene blood kit (QIAGEN Science, Maryland, USA). EDTA blood 
samples were kept frozen at -70oC, whereas clots were stored at -20oC. The blood 
samples were removed from the freezer and thawed in a 37oC water bath immediately 
before DNA extraction and transferred to 50 ml tubes (Sarstedt). The clots were 
liquidized using an OMNI TH homogenizer with disposable OMNI Tip generator 
probes, using one cycle of 20 sec.
DNA from liquidized clots (5-10ml) and EDTA blood (1-5ml) were isolated on an 
Autopure LS instrument according to protocols designed by Gentra, or manually, using 
the same reagents and protocols. In brief, RBC Lysis Solution and Cell Lysis Solution 
were added to lysate the red and white blood cells. Protein Precipitation Solution and 
Proteinase K (only for blood clots) were added to precipitate the proteins in the solution. 
Then the free DNA was precipitated in 100% isopropanol added Gentra Glycogen 
Solution (only for EDTA blood) and finally the DNA pellet was washed in 70% 
ethanol. The DNA was rehydrated in DNA Hydration Solution (Tris-EDTA-buffer).
DNA from low volumes (EDTA blood <400 l) was isolated on a GenoVision 
BioRobot GenoM-48 (QIAGEN Science, Maryland, USA) according to protocols 
designed by GenoVision.
In paper III a few DNA samples were collected from the HUNT3 survey when DNA 
was not available from HUNT2. DNA from HUNT3 was extracted from buffy-coat 
which was fractionated from 10 ml EDTA whole blood at sampling. The buffy-coat was 
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stored at -70oC at HUNT Biobank prior to DNA extraction. The DNA extraction 
protocol was in general the same as that used for the HUNT2 samples.
Selection of SNPs
The selected single nucleotide polymorphisms (SNPs) were based on publicly available 
results (mainly retrieved from searches on the PubMed database) from studies focusing
on genetic association analysis in type 1 (Table 3.1) and type 2 diabetes (Table 3.2).
Single SNP genotyping analysis
The genotyping technologies used for SNP analysis in this study were Taq-Man 
Discrimination analysis and SNPlex assay (both from Applied Biosystems, Foster City, 
CA, USA).
TaqMan Discrimination analysis
SNPs genotyped by applying TaqMan SNP allelic discrimination using ABI 7900HT
Fast Real-Time PCR System (Applied Bioasystems, Foster City, CA, USA) are 
indicated in the table 3.1 and 3.2. 
The TaqMan allelic discrimination assay is an endpoint analysis in which the presence 
of two primer and probe pairs in each reaction allows you to differentiate between two 
possible variations in a single SNP. Each probe is color labeled with its own reporter at 
the 5'-end. The reporter is a specific fluorescent (typically VIC and FAM) which helps
to distinguish between the two alleles. In addition a non-fluorescent quencher which 
suppresses the fluorescence signal of the reporter is bound at the 3'-end of the probe. 
During the amplification the probes hybridize specifically to each complementary target 
sequence (wild-type and mutant) between the primer sites. The DNA polymerase
enzyme then cleaves the reporter from the probe and quencher, resulting in increased
fluorescence signal from the reporter. The polymerase can only cleave probes
hybridized to the target sequence. The fluorescence signal generated during the 
amplification is therefore an indicator of the alleles present in the sample. After 
amplification an endpoint reading of the fluorescence signal is done using the Sequence
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Detection System (SDS) software. This software plots the signals from each sample in a
scatterplot where each signal indicates which alleles are present in the sample.
SNPlex analysis
The SNPs genotyped by applying SNPlexTM genotyping system (Applied Biosystems, 
Foster City, CA, USA) are indicated in tables 3.1 and 3.2.
The SNPlex assay is a multiplex assay which at the time of the study allowed us to 
analyse up to 48 SNPs simultaneously. The assay is a migration specific assay designed 
to discriminate alleles by the application of three SNP specific probes. Two of the 
probes are allele specific oligonucleotides (ASO) designed to discriminate the two 
alleles at each SNP. The third probe is a locus specific oligonucleotide (LSO). All 
probes have a universal PCR priming site; however, the ASO probes have a unique 
ZipCode identifier that hybridizes to the added complementary ZipChute probe. The 
ZipChute probe allows for the discrimination between the SNPs in the assay by 
providing a unique migration pattern for each SNP. Fluorescent signals from each SNP 
are interpreted by using Applied Biosystem GeneMapper Software (Applied 
Biosystems, Foster City, CA, USA).
Genotyping performance:
Cases and controls were equally distributed with four or more negative controls per 
384-plate. Criteria to pass the assay were 1) call rates >90%, 2) minor allele frequency 
(MAF) >1% in the genotyped population and 3) agreement with Hardy-Weinberg 
equilibrium in the whole population (if p-value <0.001 the assay did not pass). The SNP 
assays that did not pass quality control were excluded from further analysis.
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HLA-haplotyping
Paper I and II:
HLA-haplotyping was performed as described by de Bakker et al128. They captured 
nearby single tag SNPs or haplotypes of combination of up to three SNPs as a predictor 
of known HLA-alleles. The recommended tag SNPs or haplotypes given by deBakker et 
al. for the HLA-risk alleles for type 1 diabetes are shown in Table 3.3. We genotyped 
these tag SNPs by using the SNPlex genotyping system as described above.
Table 3.3: Genotyped tagSNPs from known risk or protective HLA alleles for type 1 
diabetes selected from supplementary table 3 in deBakker et al.128
HLA allele Frequency Tag SNPs
HLA-DQA*0101 0.1333 rs6457614,rs1794265
HLA-DQA*0102 0.2389 rs14004,rs6457594
HLA-DQA*0201 0.1333 rs7745002,rs2858333
HLA-DQA*0301 0.2278 rs3129883,rs7745002,rs3844313
HLA-DQA*0401 0.0333 rs7743506
HLA-DQA*0501 0.1778 rs10485326,rs2040406
HLA-DQB*0201 0.1556 rs4988889
HLA-DQB*0301 0.1667 rs7744001,rs2856691
HLA-DQB*0302 0.1444 rs7454108,rs2071876
HLA-DQB*0303 0.0611 rs3834857,rs2395533
HLA-DQB*0402 0.0333 rs7743506
HLA-DQB*0501 0.0944 rs6457614
HLA-DQB*0503 0.0389 rs1794265
HLA-DQB*0602 0.2000 rs3135388
HLA-DRB*0101 0.0889 rs4947332,rs6457614
HLA-DRB*0301 0.0944 rs2040410
HLA-DRB*0401 0.0889 rs6910071,rs3817964,rs660895
HLA-DRB*0402 0.0056 rs3130071,rs416352
HLA-DRB*0403 0.0167 rs7454108,rs206765,rs399604
HLA-DRB*0405 0.0056 rs1057149
HLA-DRB*0701 0.1000 rs7745002,rs2647087,rs241398
HLA-DRB*0801 0.0333 rs7743506
HLA-DRB*0901 Not reported
HLA-DRB*1101 0.0500 rs434841,rs1061172,rs5875439
HLA-DRB*1401 0.0333 rs2763979,rs1794265
HLA-DRB*1404 0.0056 rs805262,rs1794265
HLA-DRB*1501 0.2000 rs3135388
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Paper III:
HLA-DQA1 and HLA-DQB1 genotypes were analysed at the Unit for Immunology, St 
Olavs Hospital, Trondheim, Norway by sequence-specific oligonucleotide probes (SSO) 
using LABTypeR SSO DQA1/DQB1 Typing Tests (One Lambda Inc., CA, USA) as 
described by the manufacturer. In brief, the target DNA was amplified by polymerase 
chain reaction (PCR) using HLA-locus specific target primers. The amplified target 
DNA was denatured and re-hybridized with complementary DNA probes bound to 
fluorescently coded microspheres, which allowed detection using R-Phycoerytrin-bound
(PE) Strepavidin. The flow analyser Luminex 100 (Luminex Corporation, Texas, USA) 
was used to measure the fluorescent signal of PE. The HLA fusion 2.0 (One Lambda 
Inc., CA, USA) software was used to process the results.
3.4 Statistical methods
Paper I
PLINK software (http://pngu.mgh.harvard.edu/purcell/plink/)129 was used to assess
whether genotypes were in Hardy-Weinberg equilibrium and to test differences in 
genotype distribution between affected and unaffected subjects by logistic regression 
under additive, dominant and recessive models. Odds ratio (OR) and 95% confidence 
intervals (CI) were calculated. Adjustment for diabetes specific risk factors such as age, 
sex and BMI was applied when appropriate. Correction for multiple testing was done by 
max(T) permutation where 1,000 permutations were performed. Phasing HLA-
haplotypes and testing for association within cases and controls were also carried out 
using PLINK.
Paper II
Statistical Package for the Social Sciences, version 14.0 and 18.0 (SPSS Inc, Chicago) 
was used when comparing categorical data by Chi-square or Fisher’s exact test as
appropriate. Comparing continuous data between groups was done by a non-parametric 
analysis of variance test (Mann-Whitney test and Kruskal-Wallis test as appropriate). A
44
Kaplan-Mayer log-rank test was performed to assess time to insulin requirement in 
relation to antibody positivity. For comparison of antibody titer change over time (from 
HUNT2 to HUNT3) a nonparametric Wilcoxon signed Rank test for two related 
samples was used.
Paper III
Statistical analyses were performed by the PASW Statistics (version 19, SPSS, Inc, 
Chicago, IL). Chi-square test or Fisher exact test (when appropriate) was used to 
compare differences in categorical data. Mann Whitney U test was used to test 
differences in continuous data between two groups. Kruskal-Wallis test was used to test 
differences in continuous data between more than two groups. Logistic regression 
models were used to examine whether HLA haplotypes were associated with antiGAD 
after adjusting for other confounding factors such as age, gender and BMI. 
A two-tailed p-value of 0.05 was considered to be significant in all three papers.
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4 Summary of results
4.1 Paper I
Previous studies have indicated that LADA shares some genetic risk factors with type 1 
diabetes. However, data from the HUNT study indicate that LADA phenotypically may 
be more similar to type 2 diabetes. These findings suggest that LADA may share 
genetic features both with type1 and type 2 diabetes. This notion was tested by 
comparing genetic associations in type 1 and type 2 diabetes and LADA. We also tested 
whether high titres of antiGAD correlated positively with alleles conferring risk of type 
1 and negatively with alleles conferring risk of type 2 diabetes.
The type 1 diabetes genes INS (rs689 and rs3842753) and PTPN22 (rs2476601) did not
show any association with LADA. However, the most strongly associated HLA 
haplotypes for type 1 diabetes, were also found to be significantly associated with
LADA. One distinct haplotype GCA of DRB1*0401-DQA1*0301-DQB1*0301 was 
found to be associated with higher risk only of LADA (p=0.013, Table 4.1).
Table 4.1: Frequency of the two HLA-haplotypes associated only with higher risk in 
LADA compared to non-diabetic controls. 
* P-value corrected for age, sex and BMI
For the type 2 diabetes associated genes (Table 4.2), the CC/CT genotypes of rs7961581 
upstream of the TSPAN8 gene and the obesity-linked AA/AC genotypes of the SNP 
LADA
Total (n=121)
High antiGAD LADA
(n=56)
Low antiGAD LADA
(n=65)
Risk HLA-haplotypes Frequency(n) P-value*
Frequency
(n) P-value*
Frequency
(n) P-value*
DRB1*0401 - DQA1*0301 -
DQB1*0302
GCTA 0.04 (5) 0.107 0.01 (1) 0.341 0.07 (4) 0.002
DRB1*0401 - DQA1*0301 -
DQB1*0301
GCA 0.09 (11) 0.013 0.04 (2) 0.543 0.14 (9) 7.51x10-5
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rs8050126 in the FTO gene were associated with LADA. The TT/TC genotypes within 
the strongly type 2 diabetes associated TCF7L2 gene (rs7903146) were not obviously
associated with LADA.
Table 4.2: Genotypes of known type 2 diabetes associated loci in LADA compared to 
non-diabetic controls.
Gene name, SNP Genotype LADA vs. controls
Low antiGAD LADA vs. 
controls
OR (95% CI) P-value* OR (95% CI) P-value*
TCF7L2, rs7903146 CT/TT vs. CC 1.25 (0.85-1.83) 0.141
1.32 (0.78-2.24) 0.162
TSPAN8/LGR5, rs7961581 CC/CT vs. TT 1.68 (1.15-2.46) 0.01
2.17 (1.28-3.69) 0.006
FTO, rs8050136 AA/AC  vs. CC 1.94 (1.22-3.09) 0.005
2.85 (1.39-5.84) 0.003
FTO, rs1861866 CT/TT vs. CC 2.55 (1.45-4.50) 0.003
3.85 (1.52-10.0) 0.004
FTO, rs9931494 CG/GG vs. CC 2.72 (1.63-4.53) 2.43x10
-4 3.29 (1.56-6.95) 0.001
* Adjusted p-value from logistic regression for age, sex and BMI.
After dichotomising into high and low antiGAD titre the type 2 diabetes associated 
genes (Table 4.3) FTO (rs8050136, rs1861866 and rs9931491) and TSPAN8
(rs7961581) were associated only with low-antiGAD titre LADA. The strongly 
associated type 2 diabetes gene (TCF7L2, rs7903146) which was not associated with 
LADA in general, was neither associated with sub-groups of antiGAD. The HLA 
haplotypes (Table 4.1) were found to be mainly associated with high antiGAD LADA 
patients, except the GCA-haplotype for DRB1*04:01-DQA1*03:01-DQB1*03:01 which 
was associated with higher risk in low antiGAD LADA patients. Interestingly, yet 
another distinct haplotype was found, the GCTA-haplotype for DRB1*04:01-
DQA1*03:01-DQB1*03:02, which was only associated with higher risk in low 
antiGAD LADA and not with type 1 or type 2 diabetes.
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4.2 Paper II
LADA comprises a significant proportion of all diabetic cases. Yet, the etiology of 
LADA assessed by autoimmune markers is not completely clarified, nor is the 
distinction from “classical” type 1 diabetes. We investigated cross-sectionally the 
prevalence and prospectively the pre-diabetic and post-diabetic presence of antiGAD, 
antiIA-2 and antiZnT8 in LADA and in type 1 diabetes.
Cross-sectional 
LADA was positive for only one antibody in 90% of the cases (10% were multiple-
antibody-positive). Doubly and triply positive LADA patients vs. singly positive had 
lower systolic blood pressure (p=0.005), higher non-fasting blood glucose (p=0.011) 
and higher antiGAD titer (p<0.001). Age at onset was not associated with the number of 
antibodies.
Comparing LADA with adult onset type 1 diabetes (age >24 years, n=103), LADA 
patients were less frequently positive for more than one antibody (p<0.001). Those with 
LADA displayed higher levels of C-peptide (p<0.001) and antiGAD titer (p<0.001) but 
lower antiIA-2 titer (p=0.002) compared to type 1 diabetic subjects.
Prospectively
Fifty-nine percent of antiGAD-positive LADA patients in HUNT2 were no longer 
positive in HUNT3 (Table 4.3). LADA patients who became negative possessed less 
frequently risk HLA haplotypes and were phenotypically more akin to those with type 2 
diabetes than those who stayed positive. The former patients were also older at onset 
(p=0.001), more obese with both higher BMI and waist circumference (p=0.013 and 
p=0.009, respectively) and displayed higher levels of C-peptide (p=0.003). Still, those 
losing positivity differed from those with type 2 diabetes by lower C-peptide levels 
(p=0.009). Persistent antibody positivity was associated with earlier requirement of 
insulin treatment (p=0.001).
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Table 4.3: Comparison of clinical characteristics from the HUNT2 survey between 
LADA cases who participated in both HUNT2 and HUNT3 and either became antibody 
negative or stayed antibody positive during follow-up (10-13 years between HUNT2
and HUNT3)
Data presented as percentages (n) or median (min-max-value)
*Unadjusted p-value.
Of incident LADA cases in HUNT3, 21 out of 31 (68%) were already antibody-positive 
10-13 years earlier at HUNT2, i.e. before diabetes diagnosis (Table 4.4). Incident 
LADA cases who displayed antibody positivity before diagnosis were phenotypically 
more akin to type 1 diabetes than those who were antibody negative in HUNT2.
Antibody positive patients at HUNT2 were diagnosed at younger age (p=0.001) and 
were associated with higher antiGAD-titer (p=0.006) and higher fasting blood glucose 
(p=0.013) at HUNT3 than antibody negative patients.
Thirteen out of 24 incident type 1 diabetic cases (54%) were antibody positive already 
at HUNT2. There were no distinctive differences between antibody positive and 
antibody negative type 1 diabetic patients either at pre-diabetes (HUNT2) or at overt 
diabetes (HUNT3). 
LADA
Clinical characteristics HUNT2 Ab negative HUNT3 Ab positive HUNT3 P-value*
N 26 18
Age at onset (yr) 53.5 (42-75) 44.5 (21-60) 0.001
Waist circumference (cm) 96 (78-122) 88.5 (71-103) 0.009
BMI (kg/m
2
) 27.9 (24.6-44.8) 25.7 (21.9-36.9) 0.013
HDL cholesterol (mmol/l) 1.1 (0.6-2.4) 1.75 (0.7-3.3) 0.017
Triacylglycerol (mmol/l) 1.6 (0.86-4.42) 1.12 (0.44-4.48) 0.002
C-peptide (pmol/l) 492 (30-1,384) 118.5 (30-588) 0.003
Glucose, fasting (mmol/l) 7.55 (2.9-11.5) 9.0 (3.9-16.9) 0.111
GADA titer (ai) 0.11 (0.08-0.46) 0.51 (0.07-2.43) <0.001
Numbers of abs positivity 0.023
1 Ab 65% (26) 37% (14)
2-3 Abs - 100% (4)
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Table 4.4: Comparison of clinical characteristics from HUNT3 survey between 
antibody negative and antibody positive cases at HUNT2 who were diagnosed with 
LADA in HUNT3. Antibodies were measured at HUNT2 before diabetes diagnosis.
LADA
Clinical characteristics HUNT3 Ab negative HUNT2 Ab positive HUNT2 p-value*
N 10 21
Age at onset (year) 70 (57-80) 55 (31-79) 0.001
Glucose, non-fasting (mmol/l) 6.8 (5.7-12.2) 11.1 (5.0-22.4) 0.033
GADA titer (ai) 0.12 (0.08-1.09) 1.17 (0.1-2.09) 0.002
Glucose, fasting (mmol/l) 5.65 (5.2-6.0) 8.0 (5.5-19.6) 0.013
Data presented as percentages (n) or median (min-max-value)
*Unadjusted p-value.
4.3 Paper III
Development of autoimmune diabetes is strongly associated with autoantibody markers 
with high affinity towards the islet of Langerhans, such as antiGAD. Studies on the 
presence and clinical implications of antiGAD positivity in the general non-diabetic 
population are however few, especially in adults. We aimed to investigate these aspects
prospectively in a large sample of non-diabetic adults from the HUNT2 and HUNT3 
surveys.
In persistently non-diabetic individuals the prevalence of antiGAD positivity in HUNT2 
was 1.69% (n=76). Prevalence was highest in the 30-34 years age group (3.2 %, n=16).
AntiGAD positivity was not associated with sex, first degree family history of diabetes,
smoking, non-fasting glucose or BMI. There was association with the presence of 
thyroid peroxide antibody (antiTPO) positivity (p<0.025). 
AntiGAD positivity persisted at follow-up (HUNT3) in 35 out of the 76 persistently 
non-diabetic individuals (46%). Persistently non-diabetic subjects who were antiGAD 
positive at HUNT2 were compared with cases who were antiGAD positive and non-
diabetic at HUNT2 but had diabetes at HUNT3 (n=34, Table 4.5). The latter cases had 
higher frequency of first degree family history of diabetes (p=0.01), had higher 
antiGAD titre (p<0.001) and non-fasting glucose in HUNT2 (p=0.001) compared to 
those who did not develop diabetes.
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Table 4.5: Clinical characteristics of antiGAD positive and initially non-diabetic 
individuals at HUNT2, divided in persistently non-diabetic and pre-diabetic individuals.
Persistently non-diabetic*
(n=76)
Pre-diabetic†
(n=34) p-value
‡
Sex (male) 40 (52.6%) 18 (52.9%) 1.00
Waist circumference (cm) 84 (64-109) 92 (65-109) 0.03
BMI (kg/m2) 26 (19-35) 27 (18-40) 0.07
Systolic blood pressure (mmHg) 131 (102-189) 136 (107-190) 0.06
Diastolic blood pressure (mmHg) 78 (53-120) 85 (58-122) 0.09
Glucose, non-fasting (mmol/l) 5.05 (3.50-7.10) 5.60 (4.10-27.0) 0.001
Triacylglycerol (mmol/l) 1.31 (0.24-4.73) 1.62 (0.58-7.76) 0.07
AntiGAD level (ai) 0.08 (0.06-3.58) 1.43 (0.07-1.98) <0.001
First degree relative 21 (27.6%) 18 (52.9%) 0.02
Data are presented as n (%) or median (min–max values).
*Persistently non-diabetic; non-diabetic individuals at both HUNT2 and HUNT3.
†Pre-diabetic; individuals reported not having diabetes in HUNT2 and reported having 
diabetes in HUNT3. Thirteen out of these were classified as classic type 1 diabetes and 
the rest was classified as LADA (n=21).
‡Unadjusted p- value calculated by Mann–Whitney U test for continuous data and by 
Fisher’s exact test for categorical data.
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5 Discussion
5.1 Methodological considerations
The HUNT study
This study was based on subjects selected from the second and third HUNT surveys in 
the HUNT study which encompasses the population of the Nord-Trøndelag County.
This county consists of mainly rural areas and is thereby sparsely populated; however, 
the county is fairly demographically representative of Norway with regard to 
geography, economy, age distribution, morbidity and mortality. The population is stable 
and ethnically homogenous120. The HUNT study is population-based and can provide a 
long observation time. These features make the HUNT study very suitable for genetic 
and epidemiological studies on slowly developing diseases such as diabetes. However, 
there are important concerns regarding the HUNT study that needs to be addressed.
Selection bias
There has been a noticeable decrease in the attendance rate from the HUNT1 survey to 
the HUNT3 survey raising the question if non-responders could lead to increased 
selection bias over time. Because of this concern a non-responder study was carried out 
both in HUNT1 and HUNT3130,131. The attendance rate was lowest in the youngest (20-
29 years old) and oldest (80+ years old) age groups both in HUNT1 and HUNT3. The 
main reasons for not attending had not changed between the two surveys. “Had no time 
/ absent” was the most frequently reason given for not attending, especially in the 
youngest age groups whereas “too ill to attend” was the main reason amongst the oldest 
people (80+).
In the HUNT1 survey one could not find any differences in health status between 
participants and non-participants in the youngest age groups, however there was a 
selection on marital status and social network. Among the elderly the non-participants 
showed a higher frequency in mortality and morbidity indicating a more “healthy” 
population among those who participated.
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In the HUNT3 survey the prevalence of reported diabetes diagnosis (assessed by 
questionnaire) was higher among non-participants than among participants. Also the 
prevalence of diabetes was higher when based on records from the general practitioners
compared to reported diabetes diagnosis among the participants. This difference was 
most marked among those over 60 years old.
This indicates that the prevalence and incidence of diabetic cases in paper I and II may 
be underestimated. The decreasing prevalence among participants above 60 years old 
may also explain why the prevalence of LADA in HUNT3 is lower than in HUNT2 
(paper II). 
Self-reported information (information bias)
As described, the presence of diabetes in this study is based on answering affirmative to 
the question “Do you have/or have had diabetes?”. Also, the use of insulin (or use of 
any other treatment for diabetes), which was used in the classification of type of 
diabetes, was based on self-reporting. One may question the reliability in self-reported 
answers and the possibility of misclassification. Midthjell et al. performed a validation 
study regarding these aspects of the HUNT1 survey132. Correct diagnosis diabetes/no 
diabetes was verified in 96.4% of those reporting having diabetes and in 99.7% in those 
reporting not having diabetes. Regarding treatment this was verified as correct in 95% 
of those reporting using insulin and in 100% of those reporting using oral agents. A 
negative answer regarding treatment was verified in 100% and 99%, respectively. This 
indicated a very good correlation between the self-reported answers from the 
questionnaires and the medical records and a minimized possibility of misclassification 
of diabetic cases.
Antibody measurements (information bias)
By setting a cut-off of antibody positivity, it is possible that we have “recruited” falsely 
antibody positive cases. However, in paper I and II the cut-off was the same as the cut-
off used by the Aker Hormone Laboratory, which was based on data from participation 
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in DASP. The laboratory wanted highest possible specificity to ensure that the patients 
who were found to be antibody positive were true positive (correspondence with Peter 
Torjesen, Aker Hormone Laboratory, Oslo, Norway). The cut-offs in both the antiGAD 
and antiZnT8 assays had a 100% specificity and the antiIA-2 had 99% specificity
according to DASP. All assays had however a somewhat low sensitivity which will 
rather underestimate than overestimate the prevalence of antibody positive individuals. 
This may have influenced the classification of LADA and type 2 diabetes, leaving an 
underestimation of the LADA group. However, having this high cut-off will also lead to 
a more clearly defined LADA phenotype because we are more certain that these patients 
are truly antibody positive. Since the LADA group is much smaller than the type 2 
diabetic group, it is more important that the LADA cases are identified are true LADA 
than if a few LADA cases are misdiagnosed as type 2 diabetes.
Storage time of serum samples
Could long-term storage at low temperatures influence the antibody levels in serum? 
Very few studies have addressed this potential problem. One study reported that long-
term storage (>14 years) of serum at -25oC markedly increased the antiTPO level in the 
samples133. These results may indicate that there is a probability of evaporation of water 
over time from the stored serum samples that could affect the antibody level in samples. 
If evaporation of water from serum samples occurs, this may lead to increased antibody 
titer and consequently false positive antibody results. This could affect the prevalence of 
LADA cases (paper I and II) and the prevalence of antiGAD positivity in the non-
diabetic population (paper III) in our study. The serum samples used in this study,
which were collected from the HUNT2 survey, have been stored for up to 16 years 
(paper III), a time span which could potentially lead to evaporation. However, the 
HUNT serum samples have been stored at -70oC and have been exposed to a limited 
number of freeze and thaw cycles, which most likely will be better for the quality of the 
serum samples and minimize the probability of evaporation compared to storage at -
25oC.
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Classification criteria of LADA
Age, antibody positivity and independence of insulin treatment have been used in the 
past to diagnose LADA.
The age limit (usually <35 years) is to some extent arbitrary. We agree with the view of 
Rolandsson and Palmer that there should be no age limit in the classification of
LADA134.
Antibody positivity (usually anti-GAD) is regarded as a sine qua non for diagnosis of 
LADA. Is it possible to have LADA without being antibody positive? Data, from this 
study (paper II) do indicate so. About 50% of individuals with diabetes who were found
to have LADA at HUNT2 because they were antibody positive, lost anti-GAD positivity 
when they were re-examined 10-13 years later at HUNT3. Hence, if diabetes had been 
diagnosed for the first time at HUNT3 these individuals would have been classified as 
having type 2 diabetes. If one accepts that even fleeting positivity for autoimmune 
markers in diabetes does have clinical importance, then one must conclude that “mild” 
autoimmunity plays a role for developing diabetes not only for those individuals that are 
diagnosed as LADA at a given time point of examination but also for a significant part 
of those individuals who are currently diagnosed as having type 2 diabetes.
The last criterion for LADA is independence of insulin treatment at diagnosis and for a 
significant period of time thereafter. Whether an individual with new-onset diabetes is 
in need of insulin treatment is open to subjective evaluation and to current norms of 
treatment. Clearly, the insulin independence criterion is the fussiest one when defining 
LADA. Accordingly, it has been proposed to merge LADA with type 1 diabetes into a 
single category of autoimmune diabetes in adults134. Still, the insulin independence 
feature separates LADA patients phenotypically and genetically from those with adult 
onset “classical” type 1 diabetes (papers I and II). 
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Candidate gene studies
The candidate gene approach was chosen for several reasons. First: GWAS are effective 
for identification of common variants; however the effect sizes have been small with 
low odds ratios. Correction for hundreds of thousands of variants (multiple testing) is 
also essential in GWAS leading to the requirement of large sample sizes. The LADA 
group was therefore too small to consider GWAS. When this study was started there 
were already established several well-known loci associated with either type 1 diabetes 
or type 2 diabetes, identified from both candidate gene analysis and GWAS, and which 
had not been tested for associations in LADA. Candidate gene studies where therefore
at the time of investigation the most suitable approach for testing for the type 1 and type 
2 diabetes associated SNPs in the LADA patients.
5.2 Genetic and autoimmune markers associated with risk of 
developing LADA
Paper I was concerned with two important issues 1) evaluating the genetic risk factors 
for LADA and 2) assessing if genetic risk factors were dependent on the degree of 
autoimmunity (assessed by anti-GAD titre) and/or insulin resistance (assessed by BMI).
We did, as others, find that the type 1 diabetes high risk HLA haplotypes were 
associated with LADA, but still with a lower frequency compared to type 1 diabetes66,76.
The HLA risk haplotypes were also found to be mainly associated with high antiGAD 
titer LADA patients. It is well known that associations of risk HLA haplotypes diminish 
with increasing age of type 1 diabetes135. However, this does not explain altogether the 
difference in strength of association between LADA and type 1 diabetes.
Regarding type 2 diabetes genes we found two novel associations with LADA, the FTO
and TSPAN8 genes. Both genes were associated with only low antiGAD LADA,
however, the FTO gene was associated with obese LADA cases whereas the TSPAN8
gene was associated with non-obese LADA. 
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Because of the small sample size and consequently low statistical power, we may have 
failed to detect previously reported genetic associations like the non-HLA type 1 
diabetes genes INS, PTPN22, CTLA4 and the type 2 diabetes gene TCF7L276,77. Apart 
from the sample size in our study the discrepancies may also be due to the differences in 
classification criteria between ours and other studies. 
Paper II was mainly concerned with one important issue; the pre- and post-diabetic 
presence of different beta-cell antibodies in patients with LADA. We found that about 
50% of our LADA patients seroconverted to antibody negative during 10-13 years of 
follow-up (from HUNT2 to HUNT3), a percentage which was higher than previously 
reported136,137. Cases who reverted to negative were found to be phenotypically more 
similar to cases with type 2 diabetes. However, the patients with LADA displayed lower 
levels of C-peptide compared to patients with type 2 diabetic which indicates that even a 
temporary appearance of the GADA marker of autoimmunity is of clinical importance.
We have also documented that a large proportion of the LADA patients displayed 
antiGAD positivity several years before their diagnosis. This is in line with one earlier 
study that has shown that antiGAD positivity can predict development of “type 2 
diabetes” in adults114.
The existence of LADA as a subgroup of autoimmune diabetes has been 
debated118,134,138,139. In this study we have documented that the genetic risk factors for 
LADA includes both type 1 and type 2 diabetes associated genes. These differences 
indicate important etiological differences between LADA and type 1 diabetes. 
5.3 The significance of autoimmunity in a general adult non-diabetic 
population
We found an antiGAD positivity prevalence of 1.7% in our adult persistently non-
diabetic population, a prevalence which is in agreement with previous 
reports95,113,114,140. We could not find any clinical parameters conferring risk of diabetes 
that were associated with antiGAD positivity in the non-diabetic subjects. However, 
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having high risk HLA-DQA1/DQB1 haplotypes was associated with the presence of 
GAD antibodies. This associations is in line with another recent study119. Given the 
etiological importance of these haplotypes it is reasonable to conclude that even minor 
and fleeting antiGAD positivity is coupled to autoimmunity. A comparison of antiGAD 
positive persistent non-diabetic individuals with pre-diabetic antiGAD positive 
individuals revealed higher titers of antiGAD, higher BMI and age in HUNT2 in the 
latter group. This could indicate higher autoimmune activity in the pre-diabetic group as 
a cause of precipitating overt diabetes in these individuals. However, also risk factors 
for type 2 diabetes (such as age and obesity) could have contributed to the development
to diabetes.
If antiGAD or also other antibodies are to be used in classification of patients with 
diabetes as proposed by the World Health Organization and the American Diabetes 
Association, it is necessary to know the prevalence of these antibodies in the adult non-
diabetic population. The presence of antibody positivity, in particular antiGAD has been 
argued as being non-specific, not only in the non-diabetic population but also in diabetic 
cases who display low titres of antiGAD118. However, our data show that antiGAD
positivity in long term (>10 years) non-diabetic individuals associate to risk HLA 
haplotypes and also to other markers of autoimmunity (antiTPO).  Hence, the antiGAD
findings in non-diabetic individuals cannot easily be dismissed as false positives. 
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6 Conclusions
I Genetic predisposition in LADA is a mixture of both type 1 and type 2 diabetes 
associated genes. The type 1 diabetes genes are associated with LADA with 
higher degree of autoimmunity (high antiGAD titer) and the type 2 diabetes 
genes are associated with LADA with lower degree of autoimmunity (low 
antiGAD titer). 
II The dynamic patterns of antibody positivity in patients classified as LADA 
influence the phenotype of disease.
III AntiGAD positivity in adult persistently non-diabetic individuals from the 
general population is partly persistent over a long time period and is not 
associated with clinical parameters related to diabetes, but associated with high 
risk HLA haplotypes known to be associated with type 1 diabetes.
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7 Future perspectives
Since we started this study a new generation of DNA sequencing techniques have 
developed which makes it possible to identify new variants and loci contributing to 
disease risk141. Next-generation sequencing like exome sequencing and whole genome 
sequencing are now being used to detect low-frequent (<0.5%) variants. Some causal
rare variants may have large effect sizes relative to the typically small effect sizes seen
for common variants genotyped by current GWAS, and it is hypothesized that multiple 
rare variants, each occurring at low frequency but with larger effect size, may contribute 
to common diseases. The larger effect size of such variants also make re-sequencing
approaches more suitable for diseases with low sample sizes like LADA, and in this 
regard it would have been interesting to carry out exome or whole genome sequencing 
of the diabetic population from HUNT and particularly of the LADA population. This 
approach would gather genetic information beyond what can be obtained by 
conventional GWAS and might contribute to define the genetic architecture of the 
LADA phenotype.
In this study (paper II and III) antiGAD was analyzed in pre-diabetic state (at HUNT2) 
only in cases found to have autoimmune diabetes at HUNT3. It would also have been
interesting to explore the antiGAD status at a pre-diabetic state in those cases who 
developed diabetes between HUNT2 and HUNT3 but who were antiGAD negative in 
HUNT3. Another point that we did not address but which would have been interesting 
to study further is the appearance of antiGAD positivity in the entire cohort at the visit 
in HUNT3 and not only in those being antiGAD positive in HUNT2 (paper III). One 
may expect that some of the antiGAD negative individuals in HUNT2 should turn 
antiGAD positive during the follow-up. A third point would have been to screen for not 
only antiGAD but also antiIA-2, antiZnT8 and antiIA in the non-diabetic population. 
All of these points would add important and very interesting information, and clearly is 
something we will focus on in the nearest future.
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It will also be interesting to follow the as of now persistently non-diabetic individuals 
with antiGAD for possible development of diabetes in coming years (hopefully in a 
HUNT4).
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2Abstract
The presence and clinical implications of antiGAD positivity in non-diabetic populations are 
poorly elucidated. We investigated these aspects prospectively in an all-population based 
cohort from the Nord-Trøndelag health study (HUNT). We selected 4496 individuals 
(randomly from different age groups, 50% men/women) who were non-diabetic in two 
consecutive surveys, HUNT2 (1995-97) and HUNT3 (2006-08). AntiGAD positive subjects
at HUNT2 were followed up at HUNT3. HLA-DQA1/DQB1 was genotyped in antiGAD 
positive individuals and in matched antiGAD negative controls. In persisting non-diabetic 
individuals, prevalence of antiGAD positivity at HUNT2 was 1.69% (n=76). Positivity was 
not associated with gender, first degree family history of diabetes (FHD), smoking, glucose or 
BMI. However, HLA-DQA1/DQB1, a risk-haplotype for autoimmune diabetes was
associated with antiGAD positivity as was thyroid peroxidase antibody positivity. AntiGAD 
positivity was lost at follow-up (HUNT3) in 41 out of 76 individuals (54%). Results in the 
non-diabetic cohort were compared with pre-diabetic subjects (autoimmune diabetes at 
HUNT3 but non-diabetic and antiGAD positive at HUNT2, n=34). Pre-diabetic subjects had 
higher frequency of FHD, higher antiGAD levels and glucose levels. AntiGAD positivity in 
persistently non-diabetic individuals is partly consistent, is not associated with clinical 
parameters related to diabetes, but associated with HLA risk and thyroid autoimmunity. 
3Introduction
Development of autoimmune diabetes is strongly associated with the presence of 
autoantibody markers. The commonly used antibody for diagnostic purpose is against 
Glutamic Acid Decarboxylase (antiGAD). This antibody is present in over 80% of the young-
onset type 1 diabetic patients (1).
AntiGAD and other antibodies to pancreatic antigens can be detected many years before the 
clinical onset of autoimmune mediated diabetes, indicating a long pre-diabetic phase of 
autoimmune activity (2, 3). Studies which identify subjects at risk for autoimmune diabetes by 
antibodies are however mainly based on relatives of patients with type 1 diabetes (4, 5) who 
comprises only about 10% of all type 1 diabetic cases (6). There are few data available on
antibody profiling in the remaining 90% of the subjects from the general population. Previous 
studies based on adults (7-9) and school children (10, 11) have shown that antibodies, in 
particular antiGAD, are present in a proportion of non-diabetic subjects who do not have close 
relatives with autoimmune diabetes. The frequency and clinical importance of antiGAD in 
non-diabetic individuals is however still unclear and debated. It has been argued that 
positivity under these conditions do not predict developing of diabetes (12, 13), that it is 
unspecific (particularly if it is weak), and should be regarded as falsely positive (14). More 
large and prospective epidemiological studies which are population-based are needed to 
clarify this issue. 
The human leukocyte antigene (HLA) genes are strongly associated with risk of developing 
type 1 diabetes (15). HLA DQA1*0301-DQB1*0302 (DQ8) and DQA1*0501-DQB1*0201
(DQ2) are two high risk haplotypes possessed by about 90% of type 1 diabetic children (16).
It is still not fully clarified whether these haplotypes are associated or not with antiGAD 
4positivity in adult non-diabetic individuals from the general population. To our knowledge 
only one study has investigated an association in persistently non-diabetic subjects and found 
that antiGAD positivity was associated with the type 1 diabetic HLA DQA-DQB high risk 
haplotype (17).  
The primary aim of this study was to investigate the prevalence, persistence and the potential 
clinical impact of antiGAD positivity together with HLA genotypes in a non-diabetic 
population of adults. To this end we have analysed relevant data prospectively in a large non-
diabetic adult population based cohort collected from the Norwegian Health Study in Nord-
Trøndelag (HUNT). Our analysis also included tests for association between antiGAD 
positivity and other autoimmune diseases. 
Material and methods
Study population 
The study is based on the second and third health surveys (HUNT2 and HUNT3) in Nord-
Trøndelag county located in Norway. HUNT2 was performed in 1995-1997 and HUNT3 in 
2006-2008 Details about the HUNT study have been published (18). For our analysis we 
collected a random sample from the 37,059 DGXOWV\HDUVRIDJHwho took part in both 
HUNT2 and HUNT3 surveys, comprising 40% of all adults in the county. 
Equal numbers of men and women who were non-diabetic at both surveys (in the following 
termed persistently non-diabetic individuals), were randomly selected from different age 
groups: 500 individuals aged 20-29, 500 aged 30-34 etc. up to the last age group with 500 
individuals aged from 65 years and above. Altogether we sampled a total of 4,500 persistently 
non-diabetic individuals to represent the general adult population in Norway (Figure 1).
5Serum specimens to be used for antiGAD measurements were available for 4,496 of the 4,500
selected individuals from both HUNT2 and HUNT3 surveys. All individuals who were found 
to be antiGAD positive in HUNT2 were analysed for positivity in HUNT3.
We also included 55 cases with autoimmune diabetes (including both type 1 diabetes and 
LADA, Figure 1) who developed diabetes between HUNT2 and HUNT3 (i.e. reported not 
having diabetes in HUNT2 but reported having diabetes in HUNT3). Thirty-four of these 
cases were antiGAD positive already at HUNT2, i.e. several years before diagnosis. Some 
results on these cases have been published earlier (3). Diabetic cases were classified as having 
type 1 diabetes (n=13) if they started insulin treatment within 12 months of diagnosis and 
were antibody positive, or antibody negative but in addition had fasting C-peptide levels <150 
pmol/l. Cases were classified as having Latent Autoimmune Diabetes in the Adult (LADA, 
n=21) if they were antibody positive and had not been treated with insulin within 12 months 
of diagnosis. No age limit was set for LADA. Data from the patients who with time developed 
diabetes and were antiGAD positive prior to diabetes diagnosis (here called pre-diabetic 
cases, n=34) were compared with data from the population that was antiGAD positive and 
persistently non-diabetic.
Assays of antiGAD
The serum samples to be used were stored at the HUNT Biobank, Levanger, Norway, at 
minus 80oC until analysed. AntiGAD was measured at the Aker Hormone Laboratory, Oslo 
University Hospital, Oslo, Norway in 2011. AntiGAD was measured by immune precipitation 
using 3H leucine translation labelled GAD65 as reagent (Novo Nordisk, Bagsværd, Denmark). 
Separation of bound antiGAD and free labelled GAD65 was done by protein A coupled to 
6Sepharose. Antibody levels were expressed as an antibody index (ai) relative to a standard 
serum given by the formula [(counts per minute (cpm) in the patients sample – cpm from 
negative reference sample) / (cpm of a positive reference sample – cpm from negative 
reference sample)]. Subjects above the 98.5th percentile of the antiGAD levels in the total 
cohort were considered antiGAD “positive”. This corresponded to a value >0.05ai. Based on 
Aker Hormone Laboratory’s participation in the Diabetes Autoantibody Standardization 
Program (DASP) 2010, this corresponded with an 82% DASP-sensitivity and a 99% DASP-
specificity. The intra assay coefficient variation (CV) was 14% in the lowest (0.11ai), 8% in 
the middle (0.22ai) and 17% in the highest (2.0ai) range of measurements. The total CV was 
19% in the lowest (0.21ai) and 23% in the highest (0.66ai) measurements range.
HLA-typing 
Persistently non-diabetic individuals who were antiGAD positive at HUNT2 as well as a
control group of antiGAD negative non-diabetic individuals were typed for HLA- DQA1 and 
HLA- DQB1. The control group was age and gender matched to the antiGAD positive, non-
diabetic group. Two controls were selected per antiGAD positive individual. The same HLA 
genotypes were also analysed in individuals who developed autoimmune diabetes during the 
interval between HUNT2 and HUNT3.
HLA-DQA1 and HLA-DQB1 genotypes were analysed at the Unit for Immunology, St Olavs 
Hospital, Trondheim, Norway by sequence-specific oligonucleotide probes (SSO) using 
LABTypeR SSO DQA1/DQB1 Typing Tests (One Lambda Inc., CA, USA) as described by 
the manufacturer. In brief, the target DNA was amplified by polymerase chain reaction (PCR) 
using HLA-locus specific target primers. The amplified target DNA was denatured and re-
hybridized with complementary DNA probes bound to fluorescently coded microspheres, 
7which allowed detection using R-Phycoerytrin-bound (PE) Strepavidin. The flow analyser
Luminex 100 (Luminex Corporation, Texas, USA) was used to measure the fluorescent signal 
of PE and the HLA fusion 2.0 (One Lambda Inc., CA, USA) software was used to process the 
results.
The HLA DQA1-DQB1 haplotypes were divided into five groups based on known risk for 
type 1 diabetes: 1) very high risk, having both DQA1*0301-DQB1*0302 and DQA1*0501-
DQB1*0201; 2) high risk, having one of the DQA1*0301-DQB1*0302, DQA1*X-
DQB1*0302 or DQA1*0501-DQB1*0201 haplotypes (homozygosity not excluded); 3) 
moderate risk, having DQA1*X-DQB1*0201, DQA1*0101-DQB1*0501 and DQA1*0401-
DQB1*0402; 4) neutral/low-risk HLA having DQA1*X-DQB1*X; 5) very-low-risk, having 
DQA1*X-DQB1*0602 and DQA1*X-DQB1*0603. For group 2-5, X indicates a non-defined 
allele and homozygosity was not excluded.
Statistical analysis
Data are given as numbers and percentage for categorical data and as median (min-max value)
for continuous data. All statistical analyses were performed by the PASW Statistics (SPSS, 
,QF&KLFDJR,/Ȥ2 test or Fisher exact test (when appropriate) was used to compare 
differences in categorical data. Mann Whitney U test was used to test differences in 
continuous data between two groups. Kruskal-Wallis test was used to test differences in 
continuous data between more than two groups. Logistic regression models were used to 
examine whether HLA haplotypes were associated with antiGAD after adjusting for other
confounding factors such as age, gender and BMI. A two-tailed p-value of 0.05 was 
considered to be significant.
8Ethics
All participants gave their written consent. The study was approved by the Regional 
Committee for Ethics in Medical Research.
Results
Prevalence of antiGAD in persistently non-diabetic individuals 
Seventy-six out of 4496 persistently non-diabetic participants (1.69%) tested positive for 
antiGAD in HUNT2 (median level 0.08ai with min-max value of 0.06-3.58ai). The age group 
with highest prevalence was 30-34 years (16 out of 499, 3.2%). The age group with the lowest 
prevalence was 45-49 years (2 out of 499, 0.4%, Figure 2).  
AntiGAD positivity in relation to clinical data
Positivity for antiGAD was not associated with first degree family history of diabetes
(overall), smoking, non-fasting glucose or BMI (Table 1). When splitting first degree family 
history of diabetes into parents, children and siblings, there tended to be a higher risk of being 
antiGAD positive in those who had siblings with diabetes (OR [95% CI]: 1.96 [0.83-4.51], 
p=0.14, 8.2% (6 of 73 individuals) vs. 4.4% (190 of 4292 individuals)]. 
AntiGAD conversion amongst persistently non-diabetic participants
A follow-up serum sample was obtained 9-13 years later (HUNT3) from the persistently non-
diabetic participants who initially (at HUNT2) were positive for antiGAD. Of the 76 initially 
antiGAD positive adults 41 (54%) converted to negative in the follow-up sample.  
There were no phenotypic differences between antiGAD positive persisters compared to
converters (Supplementary table 1). However, the initial antiGAD levels in HUNT2 was 
9higher in those who stayed positive compared to those who converted to negative, with a 
median level (min-max value) of 0.27ai (0.06-3.58 ai) vs. 0.06ai (0.06-1.34 ai) (p<0.001 for 
difference). 
AntiGAD positive non-diabetic persisters compared to antiGAD positive pre-diabetic cases
Persistently non-diabetic subjects who were antiGAD positive at HUNT2 (n=76) were 
compared with pre-diabetic cases who were antiGAD positive and non-diabetic at HUNT2 
but had developed diabetes at HUNT3 (n=34). The pre-diabetic cases (i.e. those that 
developed diabetes) had higher frequency of first degree family history of diabetes compared 
to those who did not develop diabetes (53% (n=18) vs. 28% (n=21), p=0.02, Table 2). This 
difference was significant also after adjusting (by logistic regression) for HLA genotypes, sex, 
age and BMI (OR 2.86 [1.12-7.34], p=0.03). The individuals who turned diabetic also had 
higher antiGAD levels at HUNT2 (1.43ai [0.07-1.98 ai] vs. 0.08ai [0.06-3.58 ai], p<0.001) 
and higher non-fasting glucose (5.60mmol/l [4.10-27.0 mmol/l] vs. 5.05mmol/l [3.50-7.10
mmol/l], p=0.001) compared to the persistently non-diabetic individuals. Removing the non-
diabetic non-persistent antiGAD positive cases (i.e. in those who became antiGAD negative 
in HUNT3, n=41) from the analysis, did not affect the results (data not shown).
HLA risk haplotypes and antiGAD
Seventy-five antiGAD positive and 151 antiGAD negative persistently non-diabetic 
participants as well as 34 antiGAD positive individuals (who were pre-diabetic at HUNT2 and 
diabetic at HUNT3 were successfully genotyped for HLA DQA1-DQB1. Comparing 
antiGAD positive persistently non-diabetic individuals with antiGAD negative ones, we found 
that having the very high risk genotype DQA1*0301-DQB1*0302/DQA1*0501-DQB1*0201
(OR [95% CI]: 9.6 [2.2-42], p=0.003) or having one of the DQA1*0301-DQB1*0302,
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DQA1*X-DQB1*0302 or DQA1*0501-DQB1*0201 high risk haplotypes (OR 2.2 [1.0-4.8], 
p=0.04) was associated with being antiGAD positive (Table 3). Removing the non-persistent 
antiGAD positive cases (i.e. those who became antiGAD negative in HUNT3, n=41) from the 
analysis, did not considerably affect the results (data not shown). 
Comparing antiGAD positive persistently non-diabetic individuals with antiGAD positive 
pre-diabetic individuals, we found only a tendency for higher frequency of HLA DQA1*0301-
DQB1*0302/DQA1*0501-DQB1*0201 genotype in antiGAD positive pre-diabetic individuals 
(23.5% (n=8) vs. 10.7% (n=8), OR 2.76 [0.72-11], p=0.14). 
When combining both persistently non-diabetic and pre-diabetic antiGAD positive individuals 
in the analysis, the antiGAD level was significant higher in the high risk HLA genotypes 
compared to the weak protective HLA genotypes (p=0.001, Supplementary table 2).
AntiGAD positivity in relation to other autoimmune diseases
We tested for associations between antiGAD positivity and other self-reported immune 
mediated diseases that were asked for in the HUNT questionnaires. AntiGAD positivity 
measured in HUNT2 compared to antiGAD negativity was associated with reported 
hyperthyroidism reported in HUNT3 (7.1% (n=5) vs. 2.9% (n=120) respectively, p=0.05, 
Supplementary table 3). There was also an association with Thyroid Peroxidase antibody 
(antiTPO) positivity in both HUNT2 and HUNT3. In HUNT2, we had data on antiTPO from 
164 out of 4496 individuals. Four out of these 164 were antiGAD positive and also anti-TPO 
positive (100%), whereas 62 out of 160 (39%) antiGAD negative were antiTPO positive  
(p=0.03 for difference, Supplementary table 3). In HUNT3, we had data on antiTPO from 383 
out of 4496 individuals. Eight out of 11 (73%) antiGAD positive individuals were also 
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antiTPO positive compared to 134 out of 238 (36%) antiGAD negative ones (p=0.02 for 
difference, Supplementary table 3).
Discussion
We investigated the prevalence, evolution and clinical impact of antiGAD in a non-diabetic 
population recruited from all adults in a cohort from Norway. We also evaluated the 
associations of high risk type 1 diabetes associated HLA genotypes to the presence of 
antiGAD positivity in this non-diabetic population. 
In our adult persistently non-diabetic population we find an antiGAD positivity prevalence of 
1.7% which increases to 2.0% when including also pre-diabetic individuals. This is in fair 
agreement with previous reports in which the prevalence ranges from 1-4% in both children 
and adults from the general population (5, 8, 9, 19). However, in previous reports a 
distinction was usually not made as to whether diabetes developed over time or not, nor to 
phenotypic characteristics described here.
We observed that antiGAD in the non-diabetic population frequently changed from positivity 
to negativity over a 9-13 years period, giving a conversion rate of 54%. Seroconversion from 
antibody positive to antibody negative was associated with lower levels of antiGAD. Such 
evolution may lead one to question the clinical importance of low and fleeting antibody 
positivity. However, as elaborated below, the HLA associations constitute tangible evidence 
of importance. Further, fleeting antiGAD positivity in LADA patients was previously shown 
to impact on insulin secretion, as assessed from fasting levels of C-peptide (3).
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In the persistently non-diabetic individuals we could not find any clinical parameters 
conferring risk of diabetes that were associated with antiGAD positivity. Neither did the 
presence or absence of stability of antiGAD positivity (positivity or not both in HUNT2 and 
HUNT3) affect the clinical parameters. However, having high risk HLA DQA1-DQB1 
haplotypes were associated with presence of GAD antibodies. This is in line whit a recent
study mainly based one adult relatives of type 2 diabetic cases which found that antiGAD was 
associated with HLA high risk haplotypes regardless of family history of type 1 diabetes and 
evolution of diabetes (17). 
As mentioned above, given the etiological importance of these haplotypes it is reasonable to 
conclude that even minor and fleeting antiGAD positivity is coupled to autoimmunity.
This notion is reinforced by finding associations between antiGAD positivity and
hyperthyroidism (in this population bound to be Graves’ disease) as well as presence of
antibody towards thyroid peroxidase. An association between type 1 diabetes and thyroid 
autoimmune disease is well documented (20-22); however, an association with presence of 
antiGAD in persistently non-diabetic individuals has, to our knowledge, not been described.  
A comparison of antiGAD positive persistent non-diabetic individuals with pre-diabetic 
individuals (i.e. antiGAD positive but non-diabetic at HUNT 2, diabetic at HUNT3) revealed 
higher titers of antiGAD in HUNT2 in the latter. This could signify higher autoimmune 
activity which in turn could precipitate overt diabetes in these individuals. However, also risk 
factors for type 2 diabetes, such as BMI and age were higher and could participate in 
evolution to diabetes. In this context it will be of great interest to follow those as of now 
persistent non-diabetic individuals with antiGAD for possible evolution of diabetes in coming 
years. 
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The antiGAD level (in only antiGAD positive individuals pooled with those who also 
progressed to diabetes) was correlated with genetic risk as assessed by HLA haplotypes. This 
finding agrees with that of the Botnia Prospective Study (17). The mentioned correlation 
highlights the potential clinical importance of the risk HLA haplotypes for autoimmunity in 
adults.
We did not find an association of antiGAD positivity and overall first degree family history of 
diabetes in the non-diabetic subjects. In contrast such an association was found in the Botnia 
study (17). This difference between studies may be explained by our questionnaire data not 
being able to distinguish between type 1 and type 2 family histories of diabetes. It has been
shown in earlier studies that risk of developing type 1 diabetes and LADA is higher in 
siblings of diabetic patients compared to having parents with diabetes (23, 24).  We did see a 
tendency for higher risk of being antiGAD positive in those having siblings with diabetes. 
A limitation of this study is the sample size of the antiGAD positive individuals (both non-
diabetic and pre-diabetic) and should be considered when interpreting these results. One may 
also argue one should confirm the positivity by performing competition assays. However, this 
type of analysis has been done before and did not detect unspecific influence between anyone 
of the three different antiGAD assays tested (25). A further limitation concerns the small 
subset of the studied subjects on which the anti-TPO results are based. Therefor studies in 
other populations should be performed to confirm the present results on autoimmune thyroid 
diseases.
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We conclude that antiGAD positivity in adult non-diabetic individuals from the general 
population is 1) partly persistent over a long time period 2) not associated with clinical 
parameters related to diabetes, but associated with increased frequency of high risk HLA 
haplotypes known to be associated with type 1 diabetes and 3) associated with 
hyperthyroidism and thyroid autoimmunity. 
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Table 1: Clinical characteristics of persistently non-diabetic adult individuals stratified by 
being antiGAD negative and antiGAD positive in HUNT2.
AntiGAD negative AntiGAD positive p-value
N 4420 76 (1.7%)
Sex (male) 2208 (50%) 40 (52.6%) 0.64
Age at attendance 47.6 (19.4-85.1) 41.9 (21.3-77.1) 0.22
Waist circumference (cm) 86 (55-131) 84 (64-109) 0.69
BMI (kg/m2) 25.6 (16.2-52.8) 26.0 (19.4-34.8) 0.70
Systolic blood pressure (mmHg) 133 (82-225) 132 (102-189) 0.82
Diastolic blood pressure (mmHg) 79 (44-136) 78 (52-120) 0.85
Glucose, non-fasting (mmol/l) 5.1 (0-14.4) 5.1 (3.5-7.5) 0.89
Cholesterol (mmol/l) 5.8 (1.9-13.2) 5.7 (3.4-8.2) 0.35
HDL cholesterol (mmol/l) 1.4 (0.5-3.8) 1.3 (0.6-2.4) 0.62
Triacylglycerol b (mmol/l) 1.42 (0.31-18.6) 1.31 (0.24-4.73) 0.30
Family history of diabetes 
No 3229 55
Yes 1181 (26.8%) 21 (27.6%) 0.86
Smoking
No 3224 59
Yes 1052 (24.9%) 17 (22.4%) 0.65
Data is given as numbers (%) and median (min-max value).
Unadjusted p- value calculated by Mann–Whitney U test for continuous data and by Ȥ2 test for 
categorical data.
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Table 2: Clinical characteristics of antiGAD positive and initially non-diabetic individuals at 
HUNT2, divided in persistently non-diabetic and pre-diabetic individuals.
  Persistently non-diabetic
*
(n=76)
Pre-diabetic†
(n=34) p-value
‡
Sex (male) 40 (52.6%) 18 (52.9%) 1.00
Age at attendance 42 (21-77) 50 (26-76) 0.22
Waist circumference (cm) 84 (64-109) 92 (65-109) 0.03
BMI (kg/m2) 26 (19-35) 27 (18-40) 0.07
Systolic blood pressure (mmHg) 131 (102-189) 136 (107-190) 0.06
Diastolic blood pressure (mmHg) 78 (53-120) 85 (58-122) 0.09
Glucose, non-fasting (mmol/l) 5.05 (3.50-7.10) 5.60 (4.10-27.0) 0.001
Cholesterol (mmol/l) 5.65 (3.40-8.20) 6.00 (3.40-7.60) 0.20
HDL cholesterol (mmol/l) 1.30 (0.60-2.40) 1.30 (0.70-2.40) 0.17
Triacylglycerol (mmol/l) 1.31 (0.24-4.73) 1.62 (0.58-7.76) 0.07
AntiGAD level (ai) 0.08 (0.06-3.58) 1.43 (0.07-1.98) <0.001 
First degree relative 21 (27.6%) 18 (52.9%) 0.02
Smoking (Currently) 17 (22.4%) 12 (35.3%) 0.17
Data are presented as n (%) or median (min–max values). 
*Persistently non-diabetic; non-diabetic individuals at both HUNT2 and HUNT3. 
†Pre-diabetic; individuals reported not having diabetes in HUNT2 and reported having 
diabetes in HUNT3. Thirteen out of these were classified as classic type 1 diabetes and the 
rest was classified as LADA (n=21).
‡Unadjusted p- value calculated by Mann–Whitney U test for continuous data and by Fisher’s 
exact test for categorical data.
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Table 3: Association of HLA DQA1-DQB1 haplotypes between antiGAD negative and 
antiGAD positive persistently non-diabetic individuals.
Data are given as numbers (%).
*p- value calculated from logistic regression, corrected for age and BMI at HUNT2, sex and 
first degree family history of diabetes.
†X means non-defined allele, but does not exclude potential homozygosity.
‡Z means any haplotype.
Haplotype 1 Haplotype 2 AntiGAD
HLA 
DQA1-DQB1
HLA 
DQA1-DQB1
Negative
N=151 
Positive
N=75
OR 
(95% CI)
p-
value*
Very high 
risk 0301-0302 0501-0201 3 (2.0) 8 (10.7)
9.55
(2.16-42.2) 0.003
High risk
0301-0302/
X†-0302
0501-0201
Z‡
Z
61 (40.4) 37 (49.3) 2.22(1.03-4.80) 0.043
Moderate
risk
X-0201
0401-0402
0101-0501
0401-0402/
0101-0501/
X-X
0101-0501/
X-X
X-X
14 (9.3) 8 (10.7) 2.20(0.73-6.63) 0.159
Weak 
protective X-X X-X 31 (20.5) 10 (13.3)
1.15
(0.44-3.01) 0.776
Strong 
protective
X-0602
X-0603
X-0603/
0401-0402/
0101-0501/
X-0201
X-X
X-0602/
0401-0402/
0101-0501/
X-0201
X-X
42 (27.8) 12 (16.0) 1.00
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Legends to the figures 
Figure 1: Flow sheet over included cases followed from HUNT2 until HUNT3 
Figure 2: Prevalence of antiGAD positivity amongst the adult population in the HUNT2 
survey distributed across different age categories. 
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FIGURE 2
Supplementary table 1: Clinical characteristics from HUNT2 between antiGAD positivity 
persisters and converters in persistently non-diabetic participants. 
 AntiGAD negative AntiGAD positive p-value 
N=79 41 35   
Sex (male) 19 (46%) 21 (60%) 0.24 
Age at attendance 44.3 (21.7-77.1) 39.7 (21.3-65.9) 0.24 
Waist circumference (cm) 82 (64-120) 85 (64-106) 0.24 
BMI (kg/m2) 25.6 (19.4-34.2) 26.3 (19.4-34.8) 0.32 
Systolic blood pressure (mmHg) 131 (102-188) 132 (104-189) 0.89 
Diastolic blood pressure (mmHg) 78 (60-120) 79 (53-105) 0.81 
Glucose, non-fasting (mmol/l) 5.2 (3.5-7.5) 5.0 (3.7-7.1) 0.90 
Cholesterol (mmol/l) 5.5 (3.4-8.2) 5.8 (4.1-7.8) 0.74 
HDL cholesterol (mmol/l) 1.3 (0.7-2.4) 1.4 (0.6-2.2) 0.84 
Triacylglycerol (mmol/l) 1.3 (0.2-4.0) 1.3 (0.6-4.7) 0.73 
AntiGAD titre (ai) 0.06 (0.06-1.34) 0.27 (0.06-3.58) <0.001 
Family history of diabetes     
  No 29 26  
  Yes 12 (29.3%) 9 (25.7%) 0.80 
Smoking (Yes)    
  No 30 29  
  Yes 11 (26.8%) 6 (17.1%) 0.41 
Data presented as numbers (%) and median (min-max) value. 
Unadjusted p- value calculated by Mann–Whitney U test for continuous data and by Fisher’s 
exact test for categorical data. 
 
Supplementary table 2: AntiGAD titre in initially antiGAD positive participants in HUNT2 
stratified by HLA genotype risk and in persistently non-diabetic individuals in both HUNT2 
and HUNT3 and pre-diabetic individuals who developed diabetes during follow-up (between 
HUNT2 and HUNT3).
Haplotype 1 Haplotype 2 AntiGAD titre*
HLA 
DQA1-DQB1
HLA 
DQA1-
DQB1
Non-diabetic
N=75 
Pre-diabetic
N=34
Very high 
risk 0301-0302 0501-0201
1.11
(0.06-3.58)
1.49
(0.7-1.74)
High risk
0301-0302/
X†-0302
0501-0201
Z‡
Z
0.08
(0.06-1.82)
1.46
(0.34-1.98)
Moderate
risk
X-0201
0401-0402
0101-0501
0401-0402/
0101-0501/
X-X
0101-0501/
X-X
X-X
0.08
(0.06-2.05)
0.74
(0.25-1.36)
Weak 
protective X-X X-X
0.09
(0.06-049)
0.82 (0.07-
1.79)
Strong 
protective
X-0602
X-0603
X-0603/
0401-0402/
0101-0501/
X-0201
X-X
X-0602/
0401-0402/
0101-0501/
X-0201
X-X
0.065
(0.06-1.57 No subjects
Data are given as median (min-max value).
*AntiGAD titre was significant higher in the vhigh risk HLA genotypes compared to the weak
protective HLA genotypes (p=0.001). Data analysed by Kruskal-Wallis Test and the non-
diabetic and pre-diabetic combined.
†X means non-defined allele, but does not exclude potential homozygosity.
‡Z means any haplotype.
Supplementary table 3: Comparing antiGAD positivity with other self-reported immune 
mediated diseases in HUNT2 and HUNT3.
AntiGAD negative AntiGAD positive p- valueNo Yes No Yes
HUNT2
Anti-TPO positivity 98 (61.3%) 62 (38.8%) 0 4 (100%) 0.03
Asthma 4099 (92.8%) 319 (7.2%) 72 (94.7%) 4 (5.3%) 0.66
Hyperthyroidism 4340 (98.3%) 76 (1.7%) 73 (96.1%) 3 (3.9%) 0.15
Hypothyroidism 4293 (97.2%) 124 (2.8%) 74 (97.4%) 2 (2.6%) 1.00
Other disease in the 
thyroid gland* 4347 (99.9%) 24 (0.5%) 7 (97.4%) 2 (2.6%) 0.07
Arthritis 4269 (97.9%) 93 (2.1%) 73 (96.1%) 3 (3.9%) 0.23
Bechterews 4311 (98.2%) 77 (1.8%) 74 (97.4%) 2 (2.6%) 0.39
Allergy 3581 (82.6%) 752 (17.4%) 58 (77.3%) 17 (22.7%) 0.22
Myocrdial infarction 4351 (98.4%) 69 (1.6%) 75 (97.7%) 1 (1.3%) 1.00
HUNT3
Anti-TPO positivity 238 (64.0%) 134 (36.0%) 3 (27.3%) 8 (72.7%) 0.02
Asthma 3955 (89.5%) 465 (10.5%) 72 (94.7%) 4 (5.3%) 0.18
Hyperthyroidism 4070 (97.1%) 120 (2.9%) 65 (92.9%) 5 (7.1%) 0.05
Hypothyroidism 3954 (92.8%) 308 (7.2%) 63 (86.3%) 10 (3.1%) 0.06
Arthritis 4047 (94.7%) 226 (5.3%) 69 (93.2%) 5 (6.8%) 0.60
Bechterews 4188 (98.0%) 87 (2.0%) 72 (97.3%) 2 (2.7%) 0.66
Allergy 3000 (71.3%) 1205 (28.7%) 51 (68.9%) 23 (31.1%) 0.70
Myocrdial infarction 4233 (95.2%) 187 (4.2%) 73 (96.1%) 3 (3.9%) 1.00
Data given as absolute numbers (%)
p- value calculated by Fisher exact test because of numbers less than 5.
*Only included in the questionnaire from HUNT2
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Appendix II
Q1-HUNT3

Du inviteres herved til å delta i den tredje store Helseundersøkelsen i Nord-
Trøndelag (HUNT 3). Ved å delta får du en enkel undersøkelse av din egen helse, 
og du gir samtidig et viktig bidrag til medisinsk forskning.
Hver deltaker er like viktig, enten du er ung eller gammel, frisk eller syk, er HUNT-
veteran eller møter for første gang. Tilsvarende undersøkelse er tidligere gjennom-
ført i 1984-86 (HUNT 1) og 1995-97 (HUNT 2 og Ung-HUNT).  For å kunne studere
årsaker til sykdom, er det viktig at også de som tidligere har deltatt møter fram. 
Vennligst fyll ut spørreskjemaet, og ta det med når du møter til undersøkelse.
Undersøkelsen tar vanligvis ca 1/2 time. Du vil få brev med resultater fra dine
prøver etter noen uker. Dersom noen av resultatene er utenom det normale, vil du
bli anbefalt undersøkelse hos fastlegen din.
Du kan lese mer om HUNT 3 i den vedlagte brosjyren eller på www.hunt.ntnu.no.
Har du spørsmål, kan du også ringe til HUNT forskningssenter, tlf 74075180.
Vel møtt til undersøkelsen!
Vennlig hilsen
Steinar Krokstad Jostein Holmen Stig A. Slørdahl
Førsteamanuensis Professor, daglig leder Professor, dekanus
Prosjektleder HUNT 3 HUNT forskningssenter Det medisinske fakultet, NTNU
Dersom det foreslåtte tidspunktet ikke passer for deg, behøver du ikke
bestille ny time. Du kan møte når det passer deg innenfor åpningstiden,
men det kan da bli noe ventetid. Du kan også møte i en annen kommune,
hvis det skulle passe bedre. Takk for at du deltar!
Åpningstida: 
Invitasjon til HUNT 3
Tid og sted for oppmøte
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r b
ed
re
 fo
lke
he
lse
Vik
tig
Enk
elt
Gra
tis
VE
ST
VI
K 
RE
KL
AM
E 
AS
. F
O
TO
: H
AR
AL
D 
SÆ
TE
RØ
Y
O
G
 J
O
HA
N 
AR
N
T
N
ES
G
ÅR
D.
Slik fyller du ut skjemaet
Rett GaltX
• Skjemaet vil bli lest maskinelt. 
• Det er derfor viktig at du krysser av riktig:
• Krysser du feil sted, retter du ved å fylle boksen slik:
• Skriv tydelige tall:  
• Bruk bare svart eller blå penn. Ikke bruk blyant eller tusj.
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HELSE OG DAGLIGLIV SYKDOMMER OG PLAGER
Hvordan er helsa di nå?1
Dårlig
Har du noen langvarig (minst 1 år)
sykdom, skade eller lidelse av fysisk
eller psykisk art som nedsetter dine
funksjoner i ditt daglige liv? 
Hvor mye vil du si at dine funksjoner er nedsatt? 
2
Ikke helt god God Svært god
Ja Nei
Har du i løpet av de siste 12 måneder vært hos:6
Ja Nei
Har du vært innlagt i sykehus
i løpet av de siste 12 måneder?
7 Ja Nei
Har du kroppslige smerter nå som
har vart mer enn 6 måneder?
3
Hvor sterke kroppslige smerter har du hatt i løpet
av de siste 4 uker?
4
Ja Nei
Er bevegelseshemmet..................
Har nedsatt syn .............................
Har nedsatt hørsel ........................
Hemmet pga. kroppslig sykdom.
Hemmet pga. psykisk sykdom.....
Hjerteinfarkt ...................................
Angina pectoris (hjertekrampe) ...
Hjertesvikt ......................................
Annen hjertesykdom.....................
Hjerneslag/hjerneblødning ..........
Nyresykdom...................................
Astma .............................................
Kronisk bronkitt, emfysem, KOLS
Diabetes (sukkersyke)....................
Psoriasis..........................................
Eksem på hendene .......................
Kreftsykdom...................................
Epilepsi...........................................
Leddgikt (reumatoid artritt) ..........
Bechterews sykdom ......................
Sarkoidose .....................................
Beinskjørhet (osteoporose) ..........
Fibromyalgi ....................................
Slitasjegikt (artrose) .......................
Psykiske plager som du
har søkt hjelp for ...........................
Fastlege/allmennlege .....................................
Annen legespesialist utenfor sykehus ...........
Konsultasjon uten innleggelse 
- ved psykiatrisk poliklinikk.........................
- ved annen poliklinikk i sykehus ...............
Kiropraktor .......................................................
Homøopat, akupunktør, soneterapeut, hånds-
pålegger eller annen alternativ behandler ...
Har du hatt noe anfall med pipende
eller tung pust de siste 12 måneder?
8 Ja Nei
Har du noen gang de siste 5 år
brukt medisiner for astma, kronisk
bronkitt, emfysem eller KOLS?
9
Ja Nei
Bruker du, eller har du brukt,
medisin mot høyt blodtrykk?
10 Ja Nei
Har du noen gang fått påvist for
høyt blodsukker?
12 Ja Nei
Har du, eller har du noen
gang hatt, noen av disse
sykdommene/plagene: 
(Sett ett kryss pr. linje)
11
Mode-
rate Sterke
Meget
sterkeIngen
Meget
svake Svake
I hvilken grad har din fysiske helse eller følelses-
messige problemer begrenset deg i din vanlige
sosiale omgang med familie eller venner i løpet av
de siste 4 uker?
5
Mye
Kunne ikke
ha sosial
omgang
Ikke i det
hele tatt En del Litt
Hvis ja:
Hvis ja: I hvilken situasjon første gang?
Hvis ja, hvor gammel
var du første gang?
Litt
nedsatt
Middels
nedsatt
Mye
nedsatt
Ja Nei
Eksempel:
Ved helseundersøkelse... Under sykdom .............
Under svangerskap ......... Annet ............................
HELSETJENESTER
år 
gammel
år 
gammel
år 
gammel
år 
gammel
år 
gammel
år 
gammel
år 
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gammel
år 
gammel
år 
gammel
år 
gammel
år 
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år 
gammel
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gammel
år 
gammel
år 
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år 
gammel
år 
gammel
år 
gammel
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Lårhalsbrudd ..............................
Brudd i handledd/underarm ....
Brudd/sammenfall av ryggvirvler
Nakkesleng (whiplash)...............
Har du noen gang hatt: 13
Ja Nei
Hjerneslag eller hjerneblødning 
før 60 års alder...........................................
Hjerteinfarkt før 60-års alder ....................
Astma..........................................................
Allergi/høysnue/neseallergi......................
Kronisk bronkitt/emfysem/KOLS..............
Kreftsykdom ...............................................
Psykiske plager ..........................................
Beinskjørhet (osteoporose).......................
Nyresykdom (ikke nyresten, 
urinveisinfeksjon, urinlekkasje) .................
Diabetes (sukkersyke)................................
Har du foreldre, søsken eller barn som
har, eller har hatt, følgende sykdommer?
(Sett ett kryss pr. linje)
14
Ja Nei
Vet
ikke
Trygg og rolig?................................
Glad og optimistisk? ......................
Nervøs og urolig?...........................
Plaget av angst? .............................
Irritabel?...........................................
Nedfor/deprimert? .........................
Ensom? ............................................
Nei, jeg har aldri røykt .....................................................
Hvis du aldri har røykt, hopp til spørsmål 22.
Nei, jeg har sluttet å røyke..............................................
Ja, sigaretter av og til (fest/ferie, ikke daglig) ...............
Ja, sigarer/sigarillos/pipe av og til .................................
Ja, sigaretter daglig .........................................................
Ja, sigarer/sigarillos/pipe daglig ....................................
Har du de to siste uker følt deg:
(Sett ett kryss pr. linje)
16
LittNei
Svært
mye
En god
del
Har noen av dine besteforeldre,
dine foreldres søsken eller dine
søskenbarn fått diagnosen diabetes
(type 1 eller type 2)?
15
Ja Nei
Røykte noen av de voksne 
innendørs da du vokste opp?
18 Ja Nei
Røykte mora di da du vokste opp?19 Ja Nei
Røyker du selv? 20
Svar på dette hvis du nå røyker daglig 
eller tidligere har røykt daglig: 
Hvor mange sigaretter røyker
eller røykte du vanligvis daglig?
21
Har du noen gang i livet opplevd at
noen over lengre tid har forsøkt å
kue, fornedre eller ydmyke deg?
17 Ja Nei
sigaretter
pr. dag
Hvor gammel var du da du
begynte å røyke daglig?
Hvis du tidligere har røykt daglig,
hvor gammel var du da du sluttet?
Svar på dette hvis du røyker eller har røykt 
av og til, men ikke daglig: 
Hvor mange sigaretter røyker
eller røykte du vanligvis i måneden?
Hvor gammel var du da du 
begynte å røyke av og til?
Hvis du tidligere har røykt av og til,
hvor gammel var du da du sluttet?
Bruker du, eller har du brukt, snus?22
Hvor gammel var du da du
begynte med snus?
Hvor mange esker snus
bruker/brukte du pr. måned?
esker snus
pr. måned
A
21
B
Hvis ja:
Nei, aldri .......................... Ja, av og til...................
Ja, men jeg har sluttet.... Ja, daglig .....................
Hvis du aldri har brukt snus, hopp til spørsmål 23.
SKADER
HVORDAN FØLER DU DEG?
TOBAKK
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Hvis ja, hvor gammel
var du første gang?
Eksempel:
år 
gammel
år 
gammel
år 
gammel
år 
gammel
år 
gammel
år 
gammel
år 
gammel
sigaretter
pr. mnd
år 
gammel
år 
gammel
år 
gammel
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Hvis du bruker eller har brukt både sigaretter og 
snus, hva begynte du med først?
Omtrent hvor ofte har du i løpet av de siste 12 
måneder drukket alkohol? (Regn ikke med lettøl)
28
Hvis ja:
Har du drukket så mye at
du har kjent deg sterkt
beruset (full)? 
Da du begynte å bruke snus, var det for å prøve 
å slutte å røyke eller for å redusere røykinga? 
Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr. linje)
23
2 ggr
el mer
pr. dag
1 gang
pr. 
dag
4-6
ganger
pr. uke
1-3
ganger
pr. uke
0-3
ganger
pr. mnd
Vann, farris o.l ...............
Helmelk (søt/sur)...........
Annen melk (søt/sur) ....
Brus/saft med sukker....
Brus/saft uten sukker....
Juice eller nektar ..........
Antall kopper
Koke-
kaffe
Hvor mange glass drikker du vanligvis av følgende?
1/2 liter = 3 glass (Sett ett kryss pr. linje)
25
Aldri ..................................................................................
Sjeldnere enn en gang i uka ..........................................
En gang i uka ...................................................................
2-3 ganger i uka...............................................................
Omtrent hver dag............................................................
4 gl.
eller mer
pr. dag
2-3
gl. pr.
dag
1 gl.
pr.
dag
1-6
gl. pr
uke
Sjelden
eller
aldri
Tran ..........................................................
Omega-3-kapsler ....................................
Vitamin- og/eller mineraltilskudd..........
Bruker du følgende kosttilskudd?
(Sett ett kryss for hvert kosttilskudd)
24
Nei
Av 
og til
Ja,
daglig
ALKOHOLBRUK
MOSJON/FYSISK AKTIVITET
Hvor ofte driver du mosjon? (Ta et gjennomsnitt)32
Tar det rolig uten å bli andpusten eller svett ..............
Tar det så hardt at jeg blir andpusten og svett...........
Tar meg nesten helt ut ..................................................
Dersom du driver slik mosjon, så ofte som en eller 
flere ganger i uka; hvor hardt mosjonerer du? 
(Ta et gjennomsnitt)
33
Hvor mange kopper kaffe/te drikker du pr. døgn?
(Sett 0 dersom du ikke drikker kaffe/te daglig)
26
Hvor mange kopper kaffe
drikker du om kvelden
(etter kl 18)?
27
Antall 
kopper
Annen
kaffe Te
Antall glass
Hvor mange glass øl, vin eller brennevin drikker
du vanligvis i løpet av 2 uker? (Regn ikke med lettøl)
(Sett 0 hvis du ikke drikker alkohol)
30
Vin
Brenne-
vin
Har du drukket alkohol i løpet av
de siste 4 uker?
29 Ja Nei
Med mosjon mener vi at du f.eks går tur, går på ski,
svømmer eller driver trening/idrett.
31
Hvor lenge holder du på hver gang? 
(Ta et gjennomsnitt)
34
Snus.................................. Sigaretter......................
Omtrent samtidig .......... Husker ikke...................
(innenfor 3 måneder)
Nei.............................................. Ja, for å 
Ja, for å slutte å røyke ........... redusere røykinga........
Frukt/bær......................
Grønnsaker...................
Sjokolade/smågodt .....
Kokte poteter...............
Pasta/ris ........................
Pølser/hamburgere......
Fet fisk .........................
(laks, ørret, sild, makrell,
uer som pålegg/middag)
4-7 ganger pr. uke........... Ca 1 gang pr. måned ..
2-3 ganger pr. uke........... Noen få ganger pr. år .
ca 1 gang pr. uke ............ Ingen ganger siste år ..
2-3 ganger pr. måned..... Aldri drukket alkohol...
Nei................................
Ja, 1-2 ganger .............
Ja, 3 ganger eller mer
Hvor ofte drikker du 5 glass eller mer av øl, vin
eller brennevin ved samme anledning?
Aldri.................................. Ukentlig ........................
Månedlig ......................... Daglig...........................
Mindre enn 15 minutter.. 30 minutter – 1 time....
15-29 minutter ................. Mer enn 1 time ............
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Har du vanligvis minst 30 minutter
fysisk aktivitet daglig på arbeid
og/eller i fritida?
35 Ja Nei
Omtrent hvor mange timer sitter
du i ro på en vanlig hverdag? 
(Regn med både jobb og fritid)
36
Antall 
timer
cm Husker ikke
For det meste stillesittende arbeid 
(f.eks skrivebordsarbeid, montering) ...............................
Arbeid som krever at du går mye 
(f.eks ekspeditørarbeid, lett industriarb.,undervisning) .
Arbeid hvor du går og løfter mye
(f.eks postbud, pleier, bygningsarbeid)...........................
Tungt kroppsarbeid (f.eks skogsarbeid, tungt
jordbruksarbeid, tungt bygningsarbeid) .........................
Hvis du er i lønnet eller ulønnet arbeid, hvordan vil
du beskrive arbeidet ditt? (Sett ett kryss)
37
Omtrent hva var din høyde da du var 18 år? 38
kg Husker ikke
Omtrent hva var din kroppsvekt da du var 18 år?39
Nei, for tung
Er du fornøyd med vekta di nå?40
Nei, for lettJa
Er din kroppsvekt minst 2 kg lavere nå
enn for 1 år siden?
42 Ja Nei
Ja, mange ganger
Har du forsøkt å slanke deg i løpet av de siste 10 år? 41
Ja, noen gangerNei
Vet ikke
Hva er grunnen til dette?
Sykdom/stressSlanking
Hvis ja:
Har det vært dødsfall i nær familie?
(barn, ektefelle/samboer, søsken eller
foreldre)
43
Har du vært i overhengende livsfare
pga. alvorlig ulykke, katastrofe,
voldssituasjon eller krig?
44
Har du hatt samlivsbrudd i ekteskap
eller i lengre samboerforhold?
45
46
47
Vokste du opp på gård med husdyr?52
Hvis du har svart ja på et eller flere av spm 43, 44
eller 45; i hvilken grad har du hatt reaksjoner på
dette de siste 7 dager?
Hvem vokste du opp sammen med? 
49 Døde noen av dine
foreldre da du var barn?
50 Vokste du opp med kjæledyr?
48
53
Svært fornøyd ...................
Meget fornøyd..................
Ganske fornøyd ................
Både/og ............................
Nokså misfornøyd.........
Meget misfornøyd ........
Svært misfornøyd..........
Når du tenker på barndommen/oppveksten din, 
vil du beskrive den som:
Ble dine foreldre skilt, eller
flyttet de fra hverandre, da
du var barn?
Hvor mye melk eller yoghurt drakk du vanligvis?51
2-3 gl.
pr. dag
Mer enn
3 glass
pr. dag
Sjelden/
aldri
1-6 gl.
pr. uke
1 glass
pr. dag
Når du tenker på hvordan du har det for tida, er du
stort sett fornøyd med tilværelsen eller er du stort
sett misfornøyd? (Sett ett kryss)
54
Ja Nei
Ja Nei
Ja Nei
Ja Nei
Ikke i det hele tatt........... I moderat grad.............
Litt..................................... I høy grad.....................
Mor ................................... Andre slektninger ........
Far..................................... Adoptivforeldre ...........
Stemor/stefar................... Foster-/pleieforeldre ...
Nei ............................
Ja, før jeg var 7 år....
Ja, da jeg var 7-18 år
Nei .............................
Ja, før jeg var 7 år ....
Ja, da jeg var 7-18 år
Nei ................................
Ja, katt.............................. Ja, hund........................
Ja, hest............................. Ja, annet levende dyr .
Svært god ........................ Vanskelig ......................
God .................................. Svært vanskelig............
Middels ............................
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HØYDE/VEKT
ALVORLIGE LIVSHENDELSER SISTE 12 MÅNEDER
OPPVEKST - DA DU VAR 0-18 ÅR
ALT I ALT
Appendix III
Diabetes questionnaire HUNT2



Appendix IV
Diabetes questionnaire HUNT3
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